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ABSTRACT
Inflammation in the nervous system is a necessary part of the response to CNS infec-
tion, but can also cause neuronal damage in both infectious and autoimmune diseases
of the CNS. Sindbis virus is an enveloped, positive-strand RNA virus that infects neu-
rons and causes acute encephalomyelitis and fatal paralysis in mice. Adult C57BL/6
mice inoculated with the neurovirulent strain of Sindbis virus (NSV) succumb to fa-
tal paralysis despite clearing infectious virus from the central nervous system. The
anti-viral immune response rather than viral replication is a major contributor to
neuronal damage in NSV infection. This study has evaluated two potential methods
for treatment of alphavirus encephalomyelitis. Both methods involve small molecules
with neuroprotective properties that also inhibit the peripheral immune response in
distinct ways.
DON (6-diazo-5-oxo-l-norleucine) is a glutamine antagonist initially studied as a
chemotherapeutic for various cancers. Because glutamine is necessary for the syn-
thesis of glutamate by glutaminase, proliferating primary T-cells are very sensitive
to perturbations in glutamine metabolism. Daily intraperitoneal administration of
ii
DON to NSV-infected C57BL/6 mice inhibited the peripheral immune response to
NSV, delayed viral clearance, decreased inflammation in the CNS, and protected NSV
infected mice from fatal paralysis. However, once treatment was stopped, CNS in-
flammation appeared, infectious virus was cleared, and mice developed fatal paralysis.
Protection was associated with failure to induce an adaptive immune response in the
draining cervical lymph nodes and decreased leukocyte infiltration, lower levels of
inflammatory cytokines, and delayed viral clearance in the brain. In vitro and in vivo
studies showed that DON inhibited stimulus-induced proliferation of lymphocytes.
GYKI-52466, an AMPA receptor antagonist, was previously shown to protect
against NSV-induced fatal paralysis by being both neuroprotective and anti-inflammatory.
GYKI belongs to a class of 2,3 benzodiazepines that allosterically inhibits glutamate
gated AMPA receptors in the CNS. In this study, we demonstrated that AMPA recep-
tor antagonists directly affect lymphocyte proliferation by preventing T-cell activation
and the synthesis of IL-2. This non-canonical effect of an AMPA receptor antagonist
has implications for use in neuroinflammatory diseases.
Both treatments provide new approaches to treatment of alphavirus induced en-
cephalomyelitis.
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BBB Blood Brain Barrier.
BHK Baby Hamster Kideny.
BPTES Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide.
BrdU Bromodeoxyuridine.
BSA Bovine Serum Albumin.




CNS Central Nervous System.
CSF Cerebrospinal Fluid.
DAG Diacylglycerol.
DMEM Dulbecco’s Modified Eagle’s Medium.
DON 6-Diazo-5-oxo-L-norleucine.
EAE Experimental Autoimmune Encephalomyelitis.
ELISA Enzyme-Linked Immunosorbent Assay.
FBS Fetal Bovine Serum.
GLS1 Glutaminase isoform 1 (Kidney-type glutaminase).










NIH National Institutes of Health.
NMDA N-Methyl-D-aspartate.
NSV Neuroadapted Sindbis Virus.
PBS Phosphate Buffered Saline.
PFU Plaque Forming Units.
PMA Phorbol 12-myristate 13-acetate.
RPMI Roswell Park Memorial Institute medium.
SCID Severe Combined Immune Deficiency.
SINV Sindbis Virus Virus.
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Viral encephalomyelitis is inflammation of the brain and spinal cord as a result of
viral infection. A range of RNA and DNA viruses can cause viral encephalitis (Ta-
ble 1.1) [67]. Damage to CNS tissues can be mediated directly by the virus, in-
directly by the immune system in response to viral infection, or a combination of
both. Encephalitic viruses transmitted by arthropod vectors are an emerging public
health threat [63]. Arboviral encephalitis is relatively uncommon and geographically
restricted, but can lead to death and leave survivors with permanent neurological
deficits in survivors. Presently, there are no treatments for arboviral encephalitis
other than basic supportive care.
1.1.1 Arboviruses
Arthropod-borne viruses (arboviruses) are causes of acute encephalitis vectored by
mosquitoes, ticks, and sandflies [66]. Arboviruses that cause encephalitis in humans
are primarily RNA viruses from the Togaviridae (genus: Alphavirus) , Flaviviridae
(genus: Flavivirus), Bunyaviridae (genus: Orthobunyavirus), and Reoviridae (genus:
Coltivirus) families. Encephalitic arboviruses are generally maintained in a natural
cycle between reservoir hosts (birds, small rodents) and arthropod vectors and can be
transmitted to incidental hosts (do not amplify virus to promote transmission) such
as humans and domestic animals where they can cause clinical illness [63]. However,
some arboviruses establish an urban cycle in which humans develop sufficient viremia
to transmit the virus to competent urban arthropod vectors. Additionally, domestic
animals can also occasionally serve as amplifying hosts resulting in increased risk of
transmission to humans.
Due to its vectored transmission by arthropods, arboviral encephalitis tends to
2
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be seasonal and geographically restricted to endemic areas [66]. However, climate
change and human encroachment resulting in the redistribution and introduction
of competent arthropod vectors, movement of human populations and domesticated
animals, and viral evolution play key roles in the geographic expansion and frequency
of arboviral diseases [63,66,139,187].
This dissertation will focus on alphavirus-induced encephalomyelitis and will use
the prototypic alphavirus, Sindbis virus (SINV), in a mouse model system to study
strategies to treat acute alphavirus encephalomyelitis.
1.1.2 Alphavirus Encephalomyeltitis
Viruses in the Alphavirus genera are geographically categorized into New World
(Americas) and Old World (Europe, Asia, Africa, Australia) alphaviruses. The New
World alphaviruses, such as eastern equine encephalitis (EEE), Venezuelan equine
encephalitis (VEE), and eestern equine encephalitis (WEE) viruses, tend to be neu-
rovirulent and are a reemerging/emerging source of mortality and morbidity in hu-
mans and domestic animals, specifically horses, in the Americas. The Old World
alphaviruses such as Sindbis (SINV), Ross River (RRV), Semliki Forest (SFV) and
Chikungunya (CHIKV) viruses do not cause life-threatening disease in humans but
can cause debilitating polyarthritis resulting in significant morbidity. However, recent
case reports suggest that Old World alphaviruses, in particular CHIKV, can also be
associated with encephalitic disease in humans [30,58,127,163].
Humans and domestic animals are dead-end (incidental) hosts for most alphaviruses,
because they do not develop sufficient viremia to infect the arthropod vectors and
sustain the transmission cycle [63]. However, these incidental hosts can develop sig-
nificant clinical diseases when infected. In particular, infection with EEE results in a
3
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Rhabdoviridae Lyssavirus Australian bat lyssavirus
Rabies
Polyomaviridae§ Orthopolyomavirus JC Virus
Herpesviridae§ Herpesvirus
Herpes simplex virus
types 1 and 2
Epstein-Barr virus
Cytomegalovirus
Table 1.1: List of viruses that can cause encephalomyelitis in humans.
This is not an exhuastive list.
∗Old World alphavirus - not encephalitic in humans
†New World alphavirus - encephalitic in humans






New World Eastern Equine Encephalitis (EEE) Americas fever,encephalitis
Western equine Encephalitis (WEE) North America fever,encephalitis
Venezuelan Equine Encephalitis (VEE) Americas fever, encephalitis








Mayaro(MAY) Africa fever, rash, arthri-
tis






Table 1.2: Old and New world Alphavirus examples
high proportion of fatal encephalitis in humans (50-70% case fatality) and horses (es-
timated 70-90% case fatality) [194]. There are no current treatments for alphavirus
induced encephalitis other than supportive care. Veterinary vaccines do exist and
human vaccines are in early clinical development. There is a current lack of targeted
pharmacological countermeasures and there has been difficulty in making cross-strain
vaccines that generate robust longterm immune responses [22].
1.1.3 Bioterrorism
Alphaviruses are very easily grown to high titers in cell culture in a variety of com-
mon transformed and primary cell lines. Additionally, alphaviruses, such as VEE and
EEE, are stable and highly infectious even when aerosolized [50, 136, 143, 148, 158].
Moreover, the alphaviral genome lends itself to easy genetic manipulation by popular
recombinant DNA methods. The encephalitic New World alphaviruses, EEE, VEE,
and WEE are particularly dangerous threats due to their ability to cause significant
5
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morbidity and mortality in humans. These characteristics have motivated weaponiza-
tion of encephalitic alphaviruses. Due to their weaponization potential, VEE, WEE,
and EEE are considered Category B agents by the Centers for Disease Control (CDC).
In the past, both the United States and the former Soviet Union armed forces have
had serious offensive biological weapons programs that included the weaponization of
encephalitic alphaviruses [121]. The Biological Weapons Convention of 1972 disman-
tled the United States’s offensive biological warfare program. However, research into
defensive countermeasures against encephalitic alphaviruses continue.
1.1.4 Alphavirus Replication
Alphavirus is a genus in the family Togaviridae, that consists of viruses with en-
veloped, non-segmented, single stranded, positive sense RNA genomes of 11-12kb in
size and icosahedral capsids. The message sense RNA genome (49S RNA) is sin-
gle stranded with a 5’ cap and a poly (A) tail with two open reading frames. The
virus enters cells though receptor-mediated endocytosis via clathrin-coated pits. The
49S genomic RNA is released into the cytoplasm where translation of the first open
reading frame encoding viral nonstructural proteins (nsP1, nsP2, nsP3, nsP4) as a
polyprotein and proteolytic processing occur. The non-structural proteins assemble
from the viral replication complex and generate the full length minus-sense RNA
which serves as template for the generation of the message sense subgenomic (26S)
RNA encoding the structural polyprotein and genomic (49S) RNA. The subgenomic
(26S) RNA is translated as a polyprotein (Capsid-pE2-6K-E1). The capsid is released
cotranslationally and assembles the icosahedral nucleocapsid core by associating with
the nascent 49S genomic viral RNA via its N-terminal amino acid residues. The pE2-
6K-E1 polyprotein is translocated in the endoplasmic reticulum where it undergoes
6
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further proteolysis and posttranslational modifications to generate the mature viral
envelope proteins. The E1 and pE2 membrane glycoproteins form heterodimers and
are transported to the plasma membrane where pE2 is processed to E2 and E3 and
the cytoplasmic domain of E2 interacts with the nucleocapsid core to initiate budding.
The E1-E2 heterodimers trimerize to form spikes on the virus surface. Progeny virus
is released from the plasma membrane with E1 and E2 embedded in the host lipid
membrane bilayer. During infection the E2 protein is responsible for attachment while
E1 is responsible for fusion with the cell membrane. No definite cellular receptors or
family of receptors have been identified for alphaviruses. Because alphaviruses have a
wide host range (birds, rodents, primates, and mosquitoes) it has been hypothesized
that they might utilize either an unknown evolutionarily conserved receptor or a wide
range of cellular receptors [93].
1.1.5 Sindbis Virus
Sindbis virus (SINV), the prototypic alphavirus was first isolated from mosquitoes in
Sindbis, Egpyt in 1952 (AR339 strain) [164]. Wild type SINV causes fever, rash, and
arthritis in humans. It has a wide geographic range, but disease is only recognized
in South Africa and northern Europe. In mice, SINV causes acute encephalomyeli-
tis. In vivo, a range of factors including age, genetic background, virus strain, route
of inoculation, and immune competency determine the outcome and course of SINV
infection in mice. SINV’s trophism for neurons after intracranial or intranasal inocu-
lation makes it an ideal model for study of neurovirulence and the immune response
to CNS alphaviral infection. Additionally, this neurotrophism provides an interest-
ing model to study how neurons facilitate and respond to viral infection in general.





















































SINV has a wide host range and can be cultured in a wide variety of transformed
and primary cell lines. SINV infection of vertebrate cell lines leads to the shutdown
of host protein synthesis, loss of membrane potential, and apoptosis. The plus-strand
RNA genome makes it amenable to genetic manipulation of cDNA clones of the
virus genome. Virulent (NSV) and avirulent (TE) derivatives of the original AR3339
strain are used to study acute and long term consequences of alphaviral encephalitis.
Avirulent derivatives allow us to follow mice over the course of months and understand
host and viral factors that mediate clearance of infectious virus, understand viral RNA
persistence in neurons, and recrudescence of viral replication, and long term sequelae.
The virulent strain allows modeling of acute fatal viral encephalitis to determine
mechanisms of neuronal death and approaches to treatment.
1.1.6 NSV - A Model for Acute Fatal Viral Encephalomyelitis
Neuroadapted Sindbis Virus (NSV, Figure 1.2), was derived by serial alternating
intracranial passages of the wild type AR339 strain of SINV between suckling and
weanling BALB/c mice [68]. Compared to AR339, NSV replicates to 10-50 fold higher
titers in the brain and is virulent in both neonatal and weanling mice. Weanling mice
develop fatal encephalitis after intracranial or intranasal infection. The increase in
efficiency of replication in mature neurons and neurovirulence have been attributed
to mutations in the E1 and E2 envelope glycoproteins [107, 175, 176]. BALB/c mice
show an age-dependent resistance to NSV-induced fatal encephalitis while all ages of
C57BL/6 mice are susceptible to fatal NSV-induced disease resulting in a consistent
100% mortality even when infected with a low dose of PFU [166].
In C57BL/6 mice, NSV replicates in neurons and reaches peak titers in the brain
9
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and spinal cord earlier than in BALB/c mice. Adult C57BL/6 mice inoculated with
NSV succumb to progressive paralysis within ten days after infection (Figure 1.2B)
while adult BALB/c mice develop mild paralysis and recover from infection. The
underlying genetic determinants for the differential susceptibility of BALB/c and
C57BL/6 mice have been mapped to a region on Chromosome 2 in linkage studies
but the responsible gene has not been identified [167].
Previous studies have shown that the immune response to NSV plays a major role
in neuronal damage in adult B6 mice [90]. Survival is improved in mice deficient in
CD4+ or CD8+ T-cells and after treatment with drugs that inhibit the inflammatory
response to infection [65,89,125,147]. Animal death has been closely associated with
the death of brain and spinal cord neurons [21,74,90,99,102,141,179].
1.1.7 Noncytolytic clearance of Sindbis virus from neurons
Adult neurons are post-mitotic, terminally differentiated cells with complex intracel-
lular connections. Viral replication or the immune response to viral infection can
cause neuronal damage. In the periphery, virus is often cleared through the cytolytic
mechanisms of CD8+ cells. Because lysis of neurons can be detrimental to the host,
non-cytolytic mechanisms are necessary to control viral replication and clear infec-
tious virus without neuronal damage if the host is to recover [67]. Studies using an
avirulent strain of SINV have highlighted factors that mediate non-cytolytic clearance
of SINV in neurons. Both antibody against the E2 glycoprotein and IFN-γ produced
by CD8+ and CD4+ cells contribute to the non-cytolytic clearance of virus from
neurons [6, 15, 16, 43, 101, 116]. In the absence of IFN-γ and SINV-specific antibody
adult neurons become persistently infected.
Bi-valent antibody is required for effective clearance of virus from neurons and
10
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Figure 1.2: Profile of NSV infection in adult C57BL/6 mice.
Mice (4-6 weeks)infected i.c. with 1000pfu of virus. (A) NSV survival curve (B)
Clinical score criteria: (0) No clinical signs, (1) mild weakness (2) one hind limb
paralyzed, (3), both hind limbs paralyzed, (4) death. (C) NSV viral titers in the
brain and spinal cord (dotted line represents limit of detection). (D) Profile of the
leukocyte infiltration in the CNS measured by immunohistochemitry (E) Serurm IgG.
*Figures adapted from: [65]
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antibody-mediated clearance is independent of complement and leukocytes [69, 178].
In vitro studies have shown that treatment of SINV-infected cells with monoclonal
antibody against the E2 surface glycoprotein inhibits intracellular viral replication,
restores host protein synthesis, membrane potential, and the ability to respond to
type I interferons [43,44,67]. Furthermore, local production of antibody is necessary
for long term control of SINV replication in neurons. In immune competent mice
infectious virus is cleared from the brain and spinal cord by day 7 post infection.
However, viral RNA persists and is slowly cleared over the course of months and is
facilitated by CD8+ T-cells [89,100,177]. Passive transfer of SINV-specific antibodies
or hyperimmune serum into persistently infected, immunodeficient adult mice results
in a temporary clearance of infectious virus followed by recrudescence of infectious
virus once antibodies levels wane [90,101].
Neurons express IFN-γ receptor subunits and respond to IFN-γ through the
Jak/Stat-1 pathway. However, receptor expression and the ability to respond to
IFN-γ varies between different types of CNS neurons [16]. While SINV-specific an-
tibody can clear infectious virus from both brain and spinal cord neurons, IFN-γ
alone can clear infectious virus from spinal cord neurons but not from hippocampal
or cortical neurons [6, 17]. Treatment of SINV-infected differentiated neuronal cells
with IFN-γ increases cell survival, restores host protein synthesis, and limits viral
replication by decreasing viral transcription and protein synthesis [16,17]. Presently,
the down stream effector(s) of antibody or IFN-γ in neurons that limit SINV repli-
cation are not known, but the induction of nitric oxide (NO) may be important for
NSV infection [174]. Antibody and IFN-γ work together synergistically to control




1.1.8 The Immune Response to Sindbis Virus Infection
The Innate Immune Response
Innate cytokines play an important role in SINV spread and replication though the
production of IFN-α/β and IFN-inducible genes that inhibit virus replication [19].
Peak IFN-β levels are coincident with peak SINV titer in the brain around Day
3 post infection (Figure 1.2C). Mice deficient in interferon responses develop fatal
disease and deficiency of IFN-β results in 10-fold higher titers in the brain and spinal
cord early in infection [17]. The production of type I interferons is IRF7 (Interferon
Regulatory Factor 7)-dependent and mice defective in IRF7 succumb to NSV infection
earlier and have 10-1000 fold higher viral titers in the brain and spinal cord than wild
type mice [52,53].
Studies suggest that activated microglia, the CNS’s resident macrophages, might
be the initial source of interferons (IFN-α), inflammatory cytokines (IL12p40, IL1β,
TNF-α) and chemokines (CCL2, CCL5, CCL3, CXCL10). The mechanism by which
NSV activates microglia is still under study. A report by Esen, et al. using in vitro pri-
mary microglial cultures showed that NSV can activate multiple pattern recognition
receptors and that type I interferon production was independent of TLR signaling but
dependent on IRF7 (MyD88 KO and TLR3 KO mice show no difference in mortality
compared to wild type mice and can produce type I interferons) [52, 53]. Infiltrat-
ing myeloid cells can also produce type I interferons, inflammatory cytokines and
chemokines. The pharmacological depletion of circulating monocytes by clodronate-
loaded liposomes or the depletion of neutrophils does not alter the course of NSV-
induced fatal disease [52, 95]. Therefore, the early production of type I interferons
by CNS resident microglia might be sufficient to limit and control viral replication
13
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with NSV fatal disease might be mediated by mechanisms independent of infiltrating
myeloid cells.
Infection with NSV also results in the production of innate inflammatory cy-
tokines IL-1β, TNF-α, and IL-6 in the CNS [188]. These cytokines are produced
early by microgila and subsequently by infiltrating leukocytes and act on neuronal,
glial, and endothelial cells of the blood brain barrier. The blood brain barrier (BBB)
is a highly selective permeability layer that separates the cellular and non-cellular
soluble components of the blood from CNS parenchyma. It is composed of capillary
endothelial cells joined by tight junctions and supported by astrocytes and pericytes.
It supports the facilitated passage of essential nutrients, such as glucose, and passive
diffusion of small hydrophobic molecules and gases. However, during inflammation,
traumatic brain injury, or ischaemia the BBB becomes compromised allowing the
entry of potentially neurotoxic substances into the CNS parenchyma.
During acute inflammation, inflammatory cytokines IL-1β and TNF-α contribute
to increased permeability of the BBB and to neuronal and astrocyte dysfunction. In
addition, these cytokines prime the BBB for leukocyte entry by upregulating adhe-
sion molecules on endothelial cells that facilitate recruitment of leukocytes into the
parenchyma [78]. Hence, its not surprising that mice defective in IL-1β or treated
with antibody against IL-1β receptor are protected against fatal NSV infection, have
less paralysis, and neuronal cell death [79, 103, 141]. Adult BALB/c mice which are
resistant to NSV fatal disease show lower levels of IL-1β in the spinal cord during NSV
infection than susceptible C57BL/6 mice [141]. Similarly, mice deficient in TNF-α
have improved survival after NSV infection and less death of brain and spinal cord
neurons [21]. The contributions of IL-1β and TNF-α to NSV-induced paralysis has
14
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been attributed to their ability to perturb the clearance of the CNS’s primary exci-
tatory neurotransmitter, glutamate (see Glutamate Excitotoxicity section) [21, 141].
In vitro studies have also implicated both IL-1β and TNF-α in the up regulation of
glutaminase, the enzyme involved the the production of glutamate [191]. Hence, phar-
macological inhibition of early microglial cell activation improved survival after NSV
infection, protected spinal cord neurons, and limited severe paralysis. This result was
attributed to lower levels of IL-1β and TNF-α and improved clearance of glutamate
as a consequence [21, 79, 140, 141]. Furthermore, delaying treatment decreased the
efficacy of these interventions in protection against NSV induced mortality [79, 140].
These studies show that the early innate response plays an important role in the
outcome of NSV infection.
The Adaptive Immune Response
While type I interferons control viral replication in the CNS, the adaptive immune
response is required for clearance of infectious virus. The adaptive immune response
is induced in the superficial and deep cervical lymph nodes and peak proliferation
of lymphocytes is observed around day 5 post infection. SINV antigen presented
to antigen-specific lymphocytes in the lymph nodes results in the clonal expansion
of IFN-γ producing anti-viral CD4+/CD8+ T-cells and antibody-producing B-cells.
Early during infection B-cells produce low affinity IgM antibodies which is replaced by
production of IgG by day 7 (Figure 1.2E). Lymphocytes exit the lymph node and reach
peak CNS infiltration by day 7 post infection (Figure 1.2D). The onset of paralysis
around days 4-5 is coincident with the beginning of anti-viral T-cell infiltration and
the beginning of clearance of infectious virus from the brain and spinal cord (Figure
1.2B, C, D). By day 7 mice clear infectious virus, develop severe hindlimb paralysis,
15
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and start to die (Figure 1.2A-C).
The adaptive anti-viral T-cell immune response contributes to paralysis and fa-
tal CNS disease in NSV infection [147]. Susceptible C57BL/6 mice infected with
NSV have higher survival in TCR-α/β-deficient mice suggesting a contribution of
T-lymphocytes to NSV-induced pathology. Also, mice deficient in class I antigen
presentation (β2 microglobulin, TAP1) or CD4+ T cells have improved survival after
NSV infection. NSV-infected SCID mice develop persistent infection [188]. In ad-
dition to being a source of IFN-γ, CD8+ T-cells play an important role in clearing
viral RNA from neurons. Mice deficient in CD8+ cells have a lower rate of viral RNA
clearance compared to immunocompetent mice [89]. Recent studies have shown a role
for pathogenic Th17 cells in fatal NSV infection [95]. In total, studies suggest that
fatal disease is mediated by infiltrating anti-viral T-lymphocytes.
1.1.9 SINV-induced death in mature neurons.
SINV can infect and induce apoptosis in a range of cell types. Apoptosis is initiated
during virus entry and doesn’t require viral replication [84]. Mature neurons are less
susceptible to Sindbis virus-induced apoptosis than immature neurons. In the ab-
sence of an immune response, mature neurons become persistently infected. Though
mature adult neurons are more resistant to Sindbis virus-mediated apoptosis, these
post-mitotic and irreplaceable cells succumb to damage during clearance of NSV in-
fection suggesting that the mechanisms mediating clearance of a virulent virus are
also responsible for neurological damage with evidence of both apoptosis and necrotic
neuronal death in infected and uninfected neurons. Glutamate excitotoxicity is a
potential contributor to the bystander death of uninfected neurons during NSV infec-
tion. [39,65,124,125]. Interestingly, neurons in the brain show morphological evidence
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of both necrotic and apoptotic death during NSV infection, while spinal cord motor
neurons exclusively show signatures of necrosis [74]. This is further confirmed by the
inability to find any evidence of caspase-3 cleavage in spinal cord neurons and the
inability of viruses overexpressing anti-apoptotic proteins to protect motor neurons
from death during NSV infection [74,88].
1.1.10 Glutamate excitotoxicity
The amino acid glutamate is the principal excitatory neurotransmitter in the mam-
malian CNS where it is synthesized and stored in the neuronal cytosol and synap-
tic vesicles in millimolar concentrations. In the CNS, glutamate is not only impor-
tant in neuronal synaptic transmission but also in nervous system development, and
metabolism [126]. Extracellular concentrations of glutamate in the synaptic cleft are
kept low (nanomolar ranges) by specialized glutamate transporters on neurons and
astrocytes to prevent involuntary signaling events and to remove excess glutamate
after the completion of a signaling event, returning glutamate in the synaptic cleft to
homeostatic levels (Figure 1.3) [3]. An intact adult blood brain barrier restricts trans-
port of glutamate and glutamine into the CNS. The carbon backbone for glutamate
in the CNS is primarily derived from the catabolism of glucose molecules, neuron’s
primary energy source. Glutamate’s glucose-derived carbon backbone is continuously
recycled between glutamine and glutamate by the enzymes glutaminase (GLS1) and
glutamine synthetase (Figure 1.3). In addition to being the precursor to glutamate,
glutamine also supports the nutrient needs of neurons in hypoglycemic conditions and
is used to carry excess ammonium out of the CNS [98].
The accumulation of excess glutamate in the extracellular space as a consequence
of neuronal damage due to CNS trauma, neurodegenerative diseases, infections, and
17
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Neurons contain about 5 mM glutamate
in their cytoplasm, whereas astrocytic con-
centrations are somewhat lower9,10 — about
2–3 mM in cultured astrocytes. The lower
concentration of glutamate in astrocytes is
attributed to the presence of glutamine syn-
thetase, an enzyme that converts glutamate
to glutamine as part of the recycling of
synaptically released glutamate8,11. The exact
level of extracellular glutamate is not
known, owing to the limitations of the avail-
able techniques (BOX 1). Microdialysis
studies12,13 have consistently reported gluta-
mate levels in the range of 1–2 µM, but this
is probably an overestimation. The large
diameter of the microdialysis probes
(200–500 µm) compared with the distance
that separates brain cells (0.1–0.2 µm) might
lead to the accumulation of glutamate in the
space that is created by the probe. Unlike 
the native interstitial space, this artificial 
volume is not accessible to the membrane
transporters. In fact, the glutamate trans-
porters that are expressed by both neurons
and astrocytes (see below) have the capacity
to reduce glutamate concentrations to the
low nanomolar range14.
Release of cytosolic glutamate
Glutamate stored in synaptic vesicles is the
traditional source of extracellular glutamate.
The fact that glutamate is present at milli-
molar concentrations in the cytosol raises
the question of whether this pool is available
for release and might therefore be involved
in receptor-mediated signalling. Many stud-
ies indicate that the increase in glutamate
levels in the cerebrospinal fluid that is
observations indicate that this pool might be
released through a calcium-dependent
process, and it is possible that cytosolic glu-
tamate represents a potential transmitter
pool with functions other than its role as a
metabolic intermediary.
Here, we outline the current concepts on
the role of glutamate in non-synaptic sig-
nalling, and propose a general mechanism for
glutamate-mediated signalling between non-
excitable cells. We start by discussing the
action of glutamate on astrocytes, the pri-
mary non-excitable cell in the CNS, before
exploring the signalling role of this amino
acid in peripheral tissue.
Glutamate in the CNS
A crucial requirement for the action of glu-
tamate and other neurotransmitters in the
CNS is that their extracellular concentra-
tions be kept low. The level of glutamate in
plasma is high compared with that in cerebro-
spinal fluid. The blood–brain barrier essen-
tially prevents the entry of glutamate into
the CNS, and most of the glutamate that is
present in the brain is synthesized de novo by
astrocytes8 (FIG. 2).
Glutamate is the principal excitatory
neurotransmitter of the central nervous
system, but many studies have expanded
its functional repertoire by showing that
glutamate receptors are present in a variety
of non-excitable cells. How does glutamate
receptor activation modulate their activity?
Do non-excitable cells release glutamate,
and, if so, how? These questions remain
enigmatic. Here, we review the current
knowledge on glutamatergic signalling in
non-neuronal cells, with a special emphasis
on astrocytes.
The amino acid glutamate is recognized as the
primary excitatory neurotransmitter in the
mammalian central nervous system (CNS).
However, recent developments have shown
that glutamate receptors are broadly expressed
in tissues other than the brain by cells that
have not traditionally been associated with
glutamate-mediated signalling. For example,
the proliferation of several tumour cells is
highly sensitive to glutamate receptor antago-
nists1,2; insulin release from pancreatic β-cells
is stimulated by the glutamate receptor ago-
nists AMPA (α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid) and kainate3,4;
and glutamate receptors of the NMDA 
(N-methyl-D-aspartate) subtype are present in
osteoblasts and osteoclasts, where they affect
bone formation5.
Some of the ‘peripheral’ glutamate recep-
tors have been cloned and sequenced, and
seem to be identical to those involved in
neurotransmission6. However, the funda-
mental differences between excitable and
non-excitable cells point to different mecha-
nisms of action. For example, rapid excita-
tory currents are less likely to be important
in non-excitable cells, whereas long-term
effects on membrane potential, cytosolic cal-
cium levels and second-messenger systems
might be more relevant from a functional
perspective. A complicating factor in under-
standing the role of glutamate outside the
CNS is that this amino acid has important
roles in the intermediary metabolism and is
present at millimolar concentrations in the
cytosol of most cell types7,8 (FIG. 1). Recent
Beyond the role of glutamate as 
a neurotransmitter
Maiken Nedergaard, Takahiro Takano and Anker J. Hansen













































Figure 1 | Glutamate is a key metabolite. Nitrogen is required for the synthesis of proteins and nucleic
acids, and glutamate and glutamine are pivotal in this process. Transamination of α-ketoglutarate, an
intermediary in the citric-acid cycle, produces glutamate, whereas glutamine is synthesized by incorporation
of an ammonium ion into glutamate. The two enzymes that catalyse these reactions — glutamate
dehydrogenase and glutamine synthetase — are present in almost all life forms. Glutamate and glutamine
contribute their nitrogen to the production of several important molecules, including glutathione, polyamines
and amino sugars. GABA, γ-aminobutyric acid.
© 2002 Nature Publishing Group
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an increase in cell volume and the sub-
sequent release of glutamate and other
osmolytes through VSOACs. In fact, a recent
report supports this idea by showing that the
chloride channel blocker NPPB (5-nitro-2-
(3-phenylpropylamino)benzoate) can reduce
receptor-mediated glutamate release from
astrocytes17.
Sodium-dependent glutamate trans-
porters can also release glutamate when the
transporters operate in reverse mode36,37.
This process was first shown in isolated 
retinal Müller cells, and constitutes a main
source of extracellular glutamate in condi-
tions such as ischaemia, in which cellular ion
gradients are extinguished38. Depolarization
alone is not sufficient to reverse the action of
astrocytic glutamate transporters, and this
mechanism probably does not contribute to
calcium-dependent astrocytic glutamate
release under physiological conditions13.
However, cystine–glutamate exchangers
could contribute to the release of glu-
tamate39. These transporters exchange one
cystine molecule for one glutamate, and will
normally transport glutamate out of cells, as
the glutamate concentration is many-fold
higher inside than outside (FIG. 3). Both
observed in stroke and trauma is caused by
the efflux of cytosolic glutamate from both
neurons and astrocytes13. Although it is not
surprising that severe cellular damage is
associated with glutamate leakage, it is an
open question whether cytosolic glutamate
can be released in a regulated fashion.
It has been known for almost a decade that
astrocytes can release glutamate in response to
molecules such as prostaglandin E2, ATP, glu-
tamate and bradykinin15–17. This release is
calcium dependent and operates at physio-
logical levels of intracellular calcium18.
However, it is not clear whether glutamate is
released directly from the cytosol or whether
exocytosis is involved16. On the one hand,
astrocytes express several proteins that are
required for exocytosis, and botulinum
toxin B, which selectively cleaves the synap-
tic vesicle protein synaptobrevin, inhibits
astrocytic glutamate release19. Moreover,
astrocytic glutamate release seems to be
pulsatile and to depend on calcium20. On
the other hand, morphological studies of
astrocytes do not lend support to the exis-
tence of an exocytotic mechanism. Astrocytes
do not contain organized arrays of vesicles
near the plasma membrane, as are typically
found in secretory cells21. Instead, sparsely
distributed, unorganized vesicles can be
identified in the cytosol of astrocytes. Non-
excitable cells generally express endocytic
vesicles and the proteins that are required
for exocytosis as part of the endocytosis-
mediated recycling of membrane receptors
and ion channels22–24. Selective cleavage of
vesicle-associated proteins could therefore
affect the translocation of ion channels to
the membrane. For example, tetanus toxin
reduces the insertion of aquaporin-2 and
proton pumps into the plasma membrane
of kidney cells25,26; likewise, botulinum
toxin A decreases the insertion of NMDA
receptors through the inhibition of regu-
lated exocytosis in Xenopus oocytes27. The
observation that astrocytic glutamate
release is sensitive to bafilomycin, which
blocks a vesicle-associated H+–ATPase, has
been viewed as a strong argument in favour
of vesicular release19. However, a bafilo-
mycin-sensitive proton pump regulates the
cytosolic pH of hippocampal astrocytes,
calling into question the locus of action of
this compound28. As we discuss next, gluta-
mate release might be associated with the
activity of anion channels, and as acidification
is associated with decreased conductance 
of most anion channels29, the sensitivity of
glutamate release to bafilomycin could be
explained by an effect of this inhibitor on the
pH of the cytosol.
Astrocytes, like most other cell types,
release large quantities of cytosolic gluta-
mate as part of volume regulation. Hypo-
osmotic solutions activate volume-sensitive
organic anion channels (VSOACs) that allow
the efflux of chloride, aspartate, taurine,
glutamate and other anions in a calcium-
independent manner30–32. It is not estab-
lished whether receptor-mediated glutamate
release is associated with the activation of
VSOACs, but there is a possible link: the acti-
vation of metabotropic glutamate receptors
is associated with astrocytic swelling. So, an
increase in cytosolic calcium33–35 might cause
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Figure 2 | Compartmentalization of brain glutamate. The blood–brain barrier has a very low permeability
to glutamate (Glu). Essentially all glutamate in the brain is synthesized by transamination of α-ketoglutarate in
both neurons and glia. In glial cells, glutamate is converted to glutamine (Gln) before it is released into the
extracellular space. Glutamine is taken up by neurons and converted to glutamate before being packaged
into synaptic vesicles. Glutamate is then recycled into the transmitter pool after uptake and conversion into
glutamine by astrocytes. Glutamine also functions as a carrier of excess ammonium, and is transported
across the blood–brain barrier to be disposed of by the circulation. In young animals, the blood–brain barrier
has a higher permeability to glutamate, and excessive dietary uptake of glutamate can be excitotoxic122. 
The blood–brain barrier becomes impermeable to glutamate at seven days after birth123, and circulating
glutamate no longer represents a threat to neuronal survival after this period. The concentration of glutamate
in the cerebrospinal fluid is about 1 µM, but can increase to 20 µM under pathological conditions that are
characterized by defects in the blood–brain barrier and/or by cellular damage, such as stroke, trauma,
multiple sclerosis and meningitis14.
The fact that glutamate is
present at millimolar
concentrations in the cytosol
raises the question of
whether this pool is available
for release and might
therefore be involved in
receptor-mediated signalling.
© 2002 Nature Publishing Group
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Fi ure 1.3: Glut mate recycling i the CNS.
(A) K y steps in glutami (Gln) metab lism. (B) After signaling event, excess
glutamate (Glu) is taken up astrocytes and recycled is recycled back to glutamine by
glutamine synthetase and released into the extracellular space for uptake by neurons.
Neurons uptake th g u amine and reg nerat the n urotr nsmitter glutamate by
glutaminase (GLS1). Glutamine is also used to carry excess ammonium out of the
CNS [98]. Figures from: [126]
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deregulation of glutamate clearance results in glutamate-mediated excitotoxicity. Ac-
tivation of ionotropic glutamate receptors (AMPA, NMDA, and kainate) by excess
glutamate results in the promiscuous activation of downstream signaling cascades cul-
minating in neuronal damage and further release of intracellular glutamate affecting
nearby neurons. Compared to hippocampal and cortical neurons, spinal cord mo-
tor neurons are more susceptible to damage as a result of glutamate excitotoxicty,
possibly due to the abundance of calcium permeable AMPA receptors on motor neu-
rons [34, 125, 181]. A range of acute and chronic neurologic diseases, including viral
encephalitis, have been implicated in this pathology.
Innate cytokines, IL-1β and TNF-α, inhibit glutamate clearance by downregu-
lating the CNS’s primary glutamate transporter, GLT-1, on astrocytes during NSV
infection [21, 141]. BALB/c mice, resistant to NSV fatal infection, have 3-4 times
higher levels of GLT-1 expression in spinal cord motor neurons (this was coincident
with 4x lower IL-1β levels) compared to susceptible C57BL/6 mice [39, 141]. Sim-
ilar findings were reported for TNF-α during NSV infection. Glutamate clearance
was significantly reduced in the spinal cords of WT mice compared to TNF-deficient
mice during NSV infection. Like IL-1β, TNF-α had detrimental effects on glutamate
clearance during NSV infection [21]. Moreover, both IL-1β and TNF-α have been
implicated in the upregulation of the enzyme glutaminase (GLS1) in neuronal and
microglial cells resulting in the excess production of glutamate which can result in au-
tocrine and paracrine excitotoxicity [26, 191]. Additionally, infiltrating immune cells
can provide other sources of extracellular glutamate [114,195]. A compromised BBB
as a result of direct damage or neuroinflammation can also leak serum glutamate




AMPA and NMDA receptors are ionotropic glutamate gated ion channels that
are most implicated in glutamate excitotoxicity and pathology associated with neu-
rodegenerative diseases of the CNS including viral encephalitis [5, 7, 12, 25, 26, 73, 77,
81, 94, 105, 120, 132–134, 155, 197]. In vitro studies with cultured primary cortical
and spinal cord neurons infected with NSV have shown that bystander death of un-
infected neurons via glutamate excitotoxicity can be ameliorated using NMDA and
AMPA receptor antagonists [39, 124]. In vivo studies with NSV have shown that
treatment with NMDA and AMPA receptor antagonists protects hippocampal neu-
rons against neurodegeneration but only AMPA receptor antagonists protect both
hippocampal and spinal cord motor neurons and rescue mice from NSV-induced fa-
tal paralysis [125]. The effectiveness of the AMPA receptor antagonists, Talampanel
and GYKI-52466 (GYKI), is due to a non-competitive inhibition of AMPA receptor
signaling in neurons and to a non-canonical effect on inhibiting the induction of the
peripheral immune response [65,125]. Talampanel and GYKI-treated mice were pro-
tected against NSV-induced fatal paralysis, showed delayed viral clearance, and had
a decreased peripheral immune response as measured by draining lymph node T-cell
counts [65,125]. These drugs worked to prevent glutamate excitoxicity by binding to
AMPA receptors responding to excitotoxic glutamate on allosteric sites [4] and also
inhibited peripheral T-cell responses by an unrecognized mechanism.
1.1.11 Significance
Presently there is no treatment for acute fatal alphaviral encephalomyelitis and the
increase in disease due to mosquito-borne encephalitic viruses as a result of climate
change and human migration pose an emergent public health risk. Moreover, survivors
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of acute viral encephalitis are often left with neurological sequelae. Additionally, al-
phaviral encephalomyelitis also poses a possible bioterrorism threat. Treatments that
are both neuroprotective and immunosuppressive could help reduce high case fatality
rates and prevent permanent neurological damage in survivors of alphavirus encephali-
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Sindbis virus (SINV) is a mosquito-borne, enveloped, positive-strand RNA virus in
the family Togaviridae and genus alphavirus. SINV causes rash and arthritis in
humans and infects neurons to cause acute encephalomyelitis in mice [82] A range
of factors including age, genetic background, virus strain, route of inoculation, and
immune competency determine the outcome of infection in mice [89, 147, 166, 173].
A neuroadapted strain of SINV (NSV), obtained by serial passage in mice, causes
progressive paralysis and death of adult C57BL/6 mice and provides a model for study
of acute fatal viral encephalomyelitis [68]. Survival after NSV infection is improved in
mice deficient in CD4+ or CD8+ T-cell responses and after treatment with drugs that
inhibit the inflammatory response to infection [65,89,90,125]. The precise mechanism
by which infiltrating immune cells responding to NSV infection cause damage in
the CNS is not known, but both direct T cell-mediated cytotoxicity and glutamate
excitotoxicity have been implicated. Because the adaptive antiviral immune response
as well as glutamate excitotoxicity are potential mediators of neuronal death in NSV
infection [65, 89, 90, 95, 125, 147], we investigated the protective effects of glutamine
antagonists.
To determine if pharmacological inhibition of glutamine metabolism could pro-
tect mice from NSV-induced fatal paralysis, we treated mice with the glutamine
antagonist, DON (6-diazo-5-oxo-norleucine). DON is a Streptomyces-derived anti-
metabolite that competitively and irreversibly binds to the active sites of many
glutamine-utilizing enzymes, permanently inhibiting their catalytic activities [168].
DON was discovered in the 1950s and initially developed as a cancer chemotherapeu-
tic [32, 91]. Clinical trials from the 1980s showed that DON treatment was effective
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against tumor cells, but prolonged treatment resulted in substantial toxicity, so fur-
ther development was not pursued [48,49,108,159].
In our studies, acute treatment with relatively low doses of DON protected mice
from acute fatal encephalomyelitis and inhibited the adaptive immune response to
NSV infection. DON-induced suppression of the antiviral immune response resulted
in decreased CNS inflammation and prevented infectious virus clearance. However,
with the cessation of treatment, the appearance of the antiviral immune response
coincided along with viral clearance and fatal encephalomyelitis, confirming the role
of the immune response in disease.
2.2 Materials and Methods
2.2.1 Cell Culture and Drugs
BHK cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS),
penicillin (pen), streptomycin (strep), and 2mM glutamine (Invitrogen). Primary
lymphocytes were grown in DMEM supplemented with 10% dialyzed FBS, pen/strep,
glutamine, and 50µM β-mercaptoethanol (Sigma). Glutamine-deficient DMEM was
used in certain experiments. All cells were grown at 37℃ with 5% CO2. Glutamine
antagonists, 6-diazo-5-oxo-L-norleucine (DON; Sigma) and Acivicin (ACI; Sigma)
were solubilized in sterile PBS to prepare 100mM stock solutions. Working dilutions
were made in media for in vitro experiments or in sterile PBS for in vivo experiments.
Stock solutions were stored at -80℃ and fresh working solutions were made for each
use.
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2.2.2 Virus and plaque assay
NSV [68] was grown in BHK cells in DMEM supplemented with 1% FBS, pen/strep
and glutamine. Supernatant fluid was collected 24h after infection, filtered through a
40µM filter, and stored in aliquots at -80℃. For plaque assays supernatant fluids and
tissue homogenates (20%) were serially diluted in DMEM with 1% FBS, inoculated
onto BHK cells, incubated at 37℃ for 1h, washed and overlaid with agar (1.2%
Bactoagar, MEM, 1% FBS). After incubation for 48h at 37℃, cells were stained with
neutral red and plaques were counted.
2.2.3 Animals, infection, treatment, and tissue harvest
Six-to-eight week old female C57BL/6J mice (Jackson Laboratory) were inoculated
intracerebrally with 1000 pfu NSV in 20µL of HBSS or PBS under light isoflurane
anesthesia. Mice were treated daily with 100µL of PBS or 0.3 or 0.6 mg/kg DON
in 100-200µL PBS intraperitoneally from day 0 through day 7 after infection. Mice
were scored daily for disease using the following criteria: (0) No signs of weakness,
(1) mild weakness, hunched posture, (2) one hind limb paralyzed, (3) both hind limbs
paralyzed, and (4) death. For tissue collection, mice were deeply anesthetized and
blood was collected by cardiac puncture into serum separator tubes (BD Microtainer).
Mice were then perfused with ice cold PBS. Brain, spinal cord and cervical lymph
node tissues were collected and either used fresh for cell analysis or snap frozen and
stored at -80℃ for plaque assays and RNA extraction. All studies were done in
accordance with protocols approved by the Johns Hopkins University Animal Care
and Use Committee.
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2.2.4 qRT-PCR Analysis
RNA was extracted from frozen brains using the RNeasy Lipid Tissue Kit (Qiagen).
Extracted RNA was diluted to 1µg/µL and 2µg were reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA
(2.5µL) was analyzed for the following mRNAs by TaqMan quantitative RT-PCR:
IL-1β (mm0434228 m1), IL-6 (mm00466190 m1), TNF-α (mm99999068 m1), IL-12,
CCL2 (mm00441242 m1), CCL5 (mm01302427 m1), CXCL10(mm99999072 m1), IL-
10 (mm00439616 m1), TGF-β, IL-4 (mm00445259 m1), IFN-γ (mm00801778 m1),
T-bet (mm00450960 m1), GATA3 (mm00484683 m1), FoxP3 (mm00475162 m1), and
RoRc-γ (mm01261022 m1) (Applied Biosystems). Data were acquired on a 7500 real
time PCR machine (Applied Biosystems) and analyzed using Excel software (Mi-
crosoft). Data from all samples were normalized to rodent GAPDH (Applied Biosys-
tems) and fold induction was calculated relative to RNA from brains of uninfected
mice.
2.2.5 Histopathology and Immunohistochemistry
Deeply anesthetized mice were perfused with 20mL ice cold PBS before being per-
fused with 40mL of ice-cold 4% paraformaldehyde (PFA). Brains were harvested and
cut into 2mm coronal sections that were fixed with 4% PFA overnight at 4℃. Sec-
tions were rinsed with cold PBS, embedded in paraffin, sectioned (10µm), and stained
with hematoxylin and eosin (H&E) by the Johns Hopkins Hospital Pathology Labo-
ratory. Coded H&E sections were scored by Dr. Victoria Baxter using the following
criteria: (0) no inflammation, (1) one or two occasional inflammatory foci, (2) mod-
erate foci in <50% of 10x fields, (3) moderate-severe foci in >50% of 10x fields. A
score of +1 was given for abundant cellularity. For immunohistochemistry, sections
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were heated at 58℃ for 10 min and then rehydrated through xylene, 100% ethanol,
95% ethanol, 70% ethanol and deionized water. Sections were boiled in citrate buffer
(10mM citrate pH 6 with 0.05% Tween 20) for 10 min, cooled and washed in PBS.
Sections were blocked with 5% normal goat serum in Neuropore (Trevigen) for 30 min
and then stained with antibodies against NSV (1:100, polyclonal), CD3 (1:100, SP7
clone, Abcam) or NeuN (1:50; Millipore), overnight at 4℃ in a humidified chamber.
Slides were washed with PBST (PBS with 0.05% Tween 20) and then incubated with
appropriate fluorescently conjugated (Alexa 594 or Alexa 488, Invitrogen) secondary
antibodies diluted in Neuropore (1:200, Trevigen) for 1h at room temperature (RT).
Slides were washed in PBST, immersed in 0.1% Sudan Black in 70% ethanol for 20
min, and washed. Sections were mounted using ProLong Gold with DAPI (Invitro-
gen) for 24h in the dark at RT and images obtained using a Nikon 90i microscope with
Volocity software. Cells were counted in 10 random fields per tissue section under
20x magnification and averaged.
2.2.6 Isolation and analysis of mononuclear cells from brain and cer-
vical lymph nodes
Mononuclear cells were isolated from brain as described previously [135]. Briefly,
brains were homogenized in isotonic Percoll (9 parts Percoll; GE Healthcare, 1 part
10x HBSS; Mediatech), treated with DNase I (Sigma) for 30 min at RT and layered
onto a 30/70% discontinuous Percoll gradient. After centrifugation at 500xg for 30
min, mononuclear cells at the interface were collected. Lymph nodes were placed on
a 40µm mesh filter in a cold petri dish containing RPMI and disassociated using the
blunt end of a syringe piston.
For analysis by flow cytometry, cells were stained with Aqua Live/Dead dye (In-
vitrogen), washed with FACS buffer (PBS with 1%BSA and 2mM EDTA), blocked
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with Fc Block (BD Biosciences) for 30 min and stained with fluorescently conju-
gated antibodies against mouse CD3 (APC-Cy7, 17A2 clone, BD Biosciences), CD45
(FITC, 30-F11 clone, BD Biosciences), CD4 (PerCPCy 5.5, RM4-5 clone, BD Bio-
sciences), CD8 (PE-Cy7, 53-6.7 Clone, BD Biosciences), and CD19 (APC, 1D3 clone,
BD Biosciences). Washed cells were resuspended in 400µL FACS buffer and 50 µL of
CountBrite beads (Invitrogen) were added. Cells were analysed on a FACS Canto II
flow cytometer (BD Biosciences) for calculation of absolute numbers of live cells.
2.2.7 BrdU Incorporation Assay
BrdU (Sigma) stock (50 mg/mL) was prepared in PBS and stored in aliquots at -80
℃. BrdU (2mg in 200µL) was administered intraperitoneally on days 4 and 5 after
NSV infection. After 8h superficial cervical lymph nodes were removed and viability
determined as above. Cells were fixed, permeabilized (BD Cytofix/Cytoperm) and
then incubated in nuclear staining buffer (0.5% Triton-X 100, 1%BSA, 2mM EDTA)
for 10 min, fixed using Cytofix/Cytoperm buffer and then incubated in DNase (Sigma)
(30µg/106 cells) for 1h at 37℃. Cells were stained with FITC-conjugated antibody
to BrdU (BD Biosciences) for 20 min at RT, washed and analyzed on a FACS Canto
II flow cytometer.
2.2.8 In vitro T-cell analysis
CD3+ lymphocytes were purified from the spleens of adult C57BL/6J mice using a
Pan T-cell Isolation Kit (Miltenyi Biotec). For activation, flat bottom 96-well plates
were coated with anti-CD3 (5 µg/mL, 145-2C11 clone, eBiosciences) and anti-CD28
(2.5 µg/mL, 37.51 clone, eBiosciences) for 2h at 37℃ and washed. Prior to culture,
lymphocytes were stained with CFSE (Invitrogen) in PBS with 0.1% BSA for 5 min
at 37℃, washed, and then added at a density of 105 cells/well. Cells were cultured
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in glutamine-free or complete (DMEM, 10% dialyzed FBS, 2mM glutamine, NEAAs,
25mM HEPES) media in the presence or absence of DON or ACI 5-20µM. Cells were
stained for CD3, CD4 (PerCPCy 5.5, RM4-5 clone, BD Biosciences), and CD8 as
described above. Viability was assessed at 12h by flow cytometry (BD FACS Canto II)
using a violet fluorescent exclusion dye (Invitrogen) according to the manufacturer’s
protocol. T-cell proliferation was assessed at 72h by CFSE dilution.
2.2.9 Enzyme immunoassays
For detection of NSV-specific IgG, 96-well plates were coated overnight at 4℃ with
lysates from BHK cells infected with NSV or with uninfected BHK lysates diluted
in coating buffer (50mM NaHCO3 pH 9.6). Plates were washed with PBST (PBS
with 0.05% Tween-20), blocked with 10% FBS in PBST for 1h at RT or overnight at
4℃ and washed. Mouse serum samples diluted 1:100 in blocking buffer were added
and incubated for 1h at RT. Plates were washed and incubated with horseradish
peroxidase-conjugated antibody against mouse IgG (1:2000, Southern Biotech). Color
was developed with TMB (3,3,5,5-tetramethylbenzidine) substrate solution (Sigma).
After adding stop solution (2M H2SO4), optical densities (ODs) at 450nm were de-
termined. OD values from wells coated with uninfected BHK lysates were subtracted
to obtain NSV-specific OD values. For measurement of IFN-γ and IL-2, supernatant
fluids collected from culture media 24h after activation of CD3+ splenocytes with
anti-CD3 and CD28 were assayed for IFN-γ and IL-2 (R&D Systems). Brain ho-
mogenates diluted 1:2 were assayed for IFN-γ.
2.2.10 Statistical analysis
Statistical analysis was performed using Prism 5 software (GraphPad). Two-way
ANOVA with Bonferroni post test was used for analysis of differences between treated
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and untreated mice at different time points. Student’s t-test was used to compare
BrdU incorporation between groups. One-way ANOVA with Dunnett’s post test
was used to calculate significance for BHK viral titers and in-vitro T-cell exper-
iments. Log-rank (Mantel-Cox) test was used to compare Kaplan-Meier survival
curves. P<0.05 was considered significant.
2.3 Results
2.3.1 During treatment with DON, mice were protected from NSV-
induced acute fatal paralysis
To determine if DON could protect mice from NSV-induced fatal paralysis, infected
mice were treated daily from day 0 through 7 with either PBS or DON (0.3 mg/kg
or 0.6 mg/kg) (Figure 2.1). Most PBS-treated mice showed signs of paralysis by day
6 (Figure 2.1A) and all died by day 12 with a median day of death of 8 (Figure
2.1B). During the period of treatment, DON-treated mice had lower clinical scores
compared to PBS-treated mice (Figure 2.1A). However, once DON treatment was
stopped, paralysis developed and most mice died. Therefore, DON treatment delayed
the onset of clinical disease with a median day of death of 14 for the low dose (0.3
mg/kg) and 12 for the higher dose (0.6 mg/kg). In addition to DON we used Acivicin
(ACI), a nonspecific glutamine antagonist that is a structurally distinct from DON.
ACI was also effective in preventing acute NSV induced fatal paralysis when mice
were treated with 1mg/kg daily i.p. ( Figure 2.2).
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2.3.2 DON treatment did not affect NSV replication, but delayed
virus clearance from the brain and spinal cord.
To determine if glutamine deprivation or DON treatment affected NSV replication,
growth in BHK cells was assessed in vitro (Figure 2.3A). Cells were serum and glu-
tamine starved for 24h to deplete intracellular glutamine stores, then infected with
NSV at MOIs (multiplicity of infection) of 1 and 10, and cultured in either complete
media (DMEM without glutamine, 1% FBS, 2mM glutamine, pen/strep), glutamine-
deficient media (DMEM without glutamine, 1% dialyzed FBS, pen/strep), or com-
plete media containing glutamine antagonist DON or ACI (100µM). Virus production
was assessed at 24h. Neither glutamine deprivation nor treatment with glutamine an-
tagonists affected NSV replication in vitro (Figure 2.3A).
To examine the effects of DON treatment on virus replication and clearance in
vivo, brains and spinal cords were harvested and assayed for plaque formation on
BHK cells. DON treatment had no effect on peak viral replication with similar viral
titers in the brains and spinal cords of DON-treated and PBS-treated mice before
day 5 (Figure 2.3B). PBS-treated mice showed decreasing viral titers on day 5, but
DON-treated mice did not start to clear virus from brain until day 9, 2 days after
drug treatment was withdrawn. On days 7 and 9, DON-treated mice had 1000 to
10,000-fold higher virus titers in the brain and spinal cord than PBS-treated mice
(Figure 2.3B). Clearance of virus was associated with the onset of neurologic disease
in both DON-treated mice and PBS-treated mice(Figure 2.1).
2.3.3 DON-treated mice have less CNS lymphocyte infiltration.
To determine the effects of DON treatment on leukocyte infiltration into the brains
of NSV-infected mice, we isolated and counted brain leukocytes. Fewer leukocytes
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infiltrated the brains of DON-treated mice compared to PBS-treated mice (Figure
2.4). Total leukocyte counts (CD45+) and T lymphocyte (CD3+) counts, as well as
CD4+ and CD8+ T-cell and CD19+ B-cell counts were higher in PBS-treated mice
on days 5 and 7.
Analysis of H&E-stained coronal brain sections showed less inflammation in DON-
treated than PBS-treated mice on day 7 (Figure 2.5A,B). However, mononuclear
cells were present in the brains of surviving mice on day 13, six days after cessation
of DON treatment. A similar trend was seen with infiltrating CD3+ lymphocytes
when assessed by immunofluorescent staining (Figure 2.6A, B) with few cells in the
brains of DON-treated mice on day 7, but many cells on day 13. Cellular infiltration
was co-incident with clearance of virus as measured by detection of NSV antigen by
immunofluorescent staining (Figure 2.7A, B) and infectious virus by plaque assay
(Figure 2.3B).
Transcriptional analysis by quantitative RT-PCR for T-cell subtype-specific tran-
scription factors T-bet (Th1), FoxP3 (Treg), RoRc-γ (Th17), and GATA3 (Th2)
showed that all subsets were affected by DON treatment with the most marked effect
on expression of T-bet and FoxP3 (Figure 2.6C).
2.3.4 DON-treated mice have lower levels of cytokine and chemokine
mRNAs in brain
To investigate the effects of DON on inflammatory mediators in the CNS, brains from
DON-treated and PBS-treated NSV-infected mice were assayed for pro-inflammatory
(IL-1β, IL-6, TNF-α, IL-12), chemotactic (CCL2, CCL5, CXCL10), and anti-inflammatory
(IL-10, TGF-β, IL-4) cytokine mRNAs. PBS-treated mice had peak pro-inflammatory
mRNA expression at day 5 (Figure 2.8A). IL-1β, IL-6, and IL-12 mRNA levels de-
creased to day 1 levels by day 7 while TNF-α mRNA levels remained high longer
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(Figure 2.8A). DON-treated mice did not have an increase in pro-inflammatory cy-
tokine mRNA levels during treatment, but, with the exception of IL-6, levels in-
creased on days 9-11 after treatment was stopped(Figure 2.8A). Similarly, the brains
of DON-treated mice had lower levels of anti-inflammatory cytokine (Figure 2.8B)
and inflammatory chemokine (Figure 2.8C) mRNAs during treatment that increased
after stopping DON.
2.3.5 DON-treated mice have lower levels of IFN-γ in brain and
NSV-specific antibody in serum
CNS-infiltrating virus-specific IFN-γ-producing lymphocytes and antibody to the E2
glycoprotein contribute to the clearance of infectious virus from the brain and spinal
cord through non-cytolytic mechanisms [6,15,16,101]. Because clearance is delayed in
DON-treated mice, we measured the effect of treatment on IFN-γ mRNA and protein
levels in the brain and NSV-specific antibody in serum (Figure 2.9). In PBS-treated
control mice, IFN-γ mRNA levels peaked on day 5 after infection, and IFN-γ protein
levels peaked on day 7. In DON-treated mice, neither IFN-γ mRNA nor protein
increased during treatment. However, increases occurred on days 11 and 13 (Figure
2.9A) or 5 or 6 days following cessation of DON treatment. Similarly, NSV-specific
IgG was present in serum of PBS-treated mice on days 7-9 after infection, but mice
treated with DON produced little antibody until after treatment was stopped (Figure
2.9B). The appearance of IFN-γ in brain and antibody in serum was coincident with




2.3.6 DON-treated mice have lower lymphocyte proliferation in the
draining cervical lymph nodes after infection
The induction of the adaptive immune response to NSV infection of the brain occurs
primarily in the superficial and deep cervical lymph nodes. To determine the effects of
DON on the peripheral lymphoid cell responses to infection, superficial cervical lymph
nodes were isolated from PBS-treated and DON-treated NSV-infected mice. Cells
were stained for CD45, CD3, CD4, CD8 and CD19 and counted using a flow cytometer
(Figure 2.10). Cell counts were analyzed 5 days after infection when they peaked in
PBS-treated mice. The percentages of viable cells were similar (Figure 2.10A), as
were the proportions of CD3, CD4, CD8 and CD19-positive cells (Figure 2.10B,C).
However, there was little evidence of expansion of lymphocyte numbers in DON-
treated mice (Figure 2.10D) and this affected all populations, suggesting generalized
suppression of proliferation (Figure 2.10D-F).
To directly assess proliferation of cells in the draining lymph nodes, mice were
pulsed with the thymidine analogue BrdU 4 and 5 days after infection. Proliferat-
ing cells incorporate BrdU during the S-phase of the cell cycle and BrdU positivity
identifies cells that were proliferating during the labeling period. Lymph nodes were
harvested 8h after the second dose on Day 5 and cells assessed for BrdU incorpora-
tion via flow cytometry (Figure 2.11A). DON-treated mice had a lower percentage
(Figure 2.11B) and number (Figure 2.11C) of T-cells and B-cells incorporating BrdU
than PBS-treated mice.
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Figure 2.2: Effect of glutamine antagonist, Acivicin (ACI), on outcome of
NSV infection
Acivicin (ACI) is a glutamine antagonist that is structurally distinct from DON but
has similar mechanism of action. Like DON, ACI is non-specific glutamine antagonist.
C57BL/6 mice (N=5 per group) were infected with 1000 pfu of NSV intracerebrally
and treated every 24h intraperitoneally with ACI ( 1 mg/kg) or PBS vehicle (200µL)
i.p. through day 7. ACI-treated mice had a lower clinical scores during treatment
and 40% lower mortality after Day 9 compared to PBS treated mice. ***P<0.001




























































 NSV  NSV + DON
Figure 2.3: Effect of glutamine deprivation on virus replication.
(A) Viral titers from NSV infection of BHK cells at MOIs of 1 and 10 in either
complete media (Gln(+)), glutamine-deficient media (Gln(-)), or complete media with
glutamine antagonists 6-Diazo-5-oxo-L-norleucine (DON 100µM) or Acivicin (ACI -
100µM). BHK cells were glutamine and serum-starved for 24 h before infection with
NSV. Supernatant fluids were collected 24 h after infection and assayed by plaque
formation on BHK cells. Difference between Glu(+) and other treatment groups
were not significant either at MOI of 10 or 1. (B) Viral titers from the brains
and spinal cords of PBS (NSV) and DON-treated (NSV + DON, 0.6 mg/kg-brain,
0.3mg/kg spinal cord) mice. Grey bars under the x-axis designate the drug treatment
period. Error bars represent SEM of the geometric mean viral titers of three biological
replicates (A) or three mice (B). The dotted line represents the limit of detection
of the plaque assay. Data are representative of at least two independent experiments
(B). *P<0.05; ***P<0.001 (One way ANOVA with Dunnetts post test (A), Two-way
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Treatment for seven days with the glutamine antagonist DON protected mice from
NSV-induced acute fatal paralysis. DON prevented induction of the anti-viral immune
response, resulting in decreased CNS inflammation and a failure to clear infectious
virus from the brain and spinal cord. Analysis of draining cervical lymph node cells
showed that proliferation of B cells, and CD4+ and CD8+ T cells was prevented
by DON treatment in infected mice. Mice that survived acute infection as a result
of treatment succumbed to NSV-induced fatal encephalomyelitis after treatment was
stopped, coincident with appearance of the anti-viral immune response, increased
CNS inflammation and virus clearance.
Treatment with DON prevented the growth and proliferation of peripheral lym-
phocytes involved in the anti-viral immune response leading to decreased CNS lym-
phocyte infiltration and delayed viral clearance. Production of IFN-γ and NSV-
specific IgG, both important for virus clearance, were compromised in DON-treated
mice. A role for the antiviral immune response in disease is empirically supported
by the appearance of the pro-inflammatory, chemotactic, anti-inflammatory, and T-
cell transcription factor mRNA expression in the brain after DON treatment was
stopped. Previous studies have shown that susceptible C57BL/6 mice that are defi-
cient in TCR-α/β in class I antigen presentation (β2 microglobulin, TAP1) or CD4+
T cells have improved survival after NSV infection and that IL-10-deficient mice have
accelerated disease, suggesting that T-cells have a prominent role in NSV pathol-
ogy [89,95,147]. However, neither the pharmacological depletion of circulating mono-
cytes by clodronate-loaded liposomes nor the depletion of neutrophils alters the course
of NSV-induced fatal disease [52,95].
47
2.4. DISCUSSION
These data suggest that T-cells are the primary mediators of neuronal damage in
NSV-induced acute encephalitis. How T-cells mediate disease is still unknown, and
prevention of disease development by DON may be through more than one mechanism.
Previous studies have implicated glutamate excitotoxicity. Neurotropic infections of
the CNS can lead to glutamate excitotoxicity both through direct neuronal damage
and immune-mediated neuronal injury [7, 12, 13, 65, 125]. Cultured primary cortical
and spinal cord neurons infected with NSV develop direct and bystander neuronal
death via glutamate excitotoxicity, which can be ameliorated using antagonists of the
NMDA and AMPA ionotropic glutamate receptors [39, 124]. In NSV-infected mice,
treatment with NMDA and AMPA receptor antagonists protects hippocampal neu-
rons against neurodegeneration, but only AMPA receptor antagonists protect spinal
cord motor neurons and prevent NSV-induced fatal paralysis [65, 125]. Surprisingly,
mice treated with AMPA receptor antagonists also showed delayed viral clearance, a
decreased peripheral immune response and less CNS inflammation. Therefore, treat-
ment with DON produced a similar outcome as treatment with AMPA receptor an-
tagonists through a very different mechanism.
DON may prevent the generation of neurotoxic glutamate as well as inhibit the
growth and proliferation of lymphocytes in peripheral lymphoid tissue. DON is effec-
tive in preventing the generation of glutamate from microglial cells and macrophages,
and mitigation of disease in experimental autoimmune encephalomyelitis by DON is
assumed to be due to prevention of this excitotoxic glutamate release [155]. However,
as the current study has shown, DON also has potent inhibitory effects on induction of
the immune response without affecting NSV replication in vitro or in vivo. Moreover,
glutamine deprivation and treatment with drugs that inhibit glutamine metabolism
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may have a direct effect on virus replication [31,56,64,76,80,129,144]. Although glu-
tamine deprivation is reported to reduce titers of SINV produced by BHK cells [80],
we were unable to replicate these effects, as neither glutamine deprivation nor DON
treatment affected NSV viral titers in our studies.
However, DON is a relatively nonspecific inhibitor of all glutamine-utilizing en-
zymes and at high doses has been associated with substantial toxicity [49, 159]. We
have shown that acute treatment with low doses of DON is relatively well tolerated.
GLS1, the major glutaminase involved in the generation of glutamate in the CNS [51],
is also the glutaminase that is up regulated in T-cells during activation and has an
central role in glutamine metabolism, cell cycle progression, and signaling in rapidly
proliferating cells [23,33,47,62,97,169,185]. Because GLS1 plays a critical role in the
nervous system as well as in the peripheral immune system, development of GLS1-
specific inhibitors might offer a more specific, targeted and less toxic way to treat
neuroinflammatory disease. Limiting neurotoxic glutamate production by neuronal
and microglial cells in the CNS, as well as modulating the peripheral lymphocyte
response, is a promising approach to treatment of viral encephalomyelitis. In future
studies we plan to investigate the effect of specific glutaminase (GLS1) inhibitors on
CNS glutamate excitotoxicity during NSV infection.
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3.1.1 Glutamine metabolism in lymphocytes
T-cells preferentially use glutamine rather than glucose for metabolic needs during
growth and proliferation [109]. Increased glutamine uptake and metabolism are char-
acteristic of rapidly dividing cells such as activated T-cells and certain cancer cells
where glutamine is used as an energy and nitrogen source [23]. Proliferating T-cells
require millimolar concentrations of extracellular glutamine for growth and cell cycle
progression [23]. T-cells stimulated in glutamine-deprived media fail to expand in
size, replicate their DNA, or enter S-phase of the cell cycle [54, 118]. Additionally,
silencing key enzymes involved in glutamine metabolism such as phosphate-activated
glutamininase (GLS1), which is upregulated during T-cell activation, completely in-
hibits proliferation of human T-cells [33]. These studies suggest that availability and
metabolism of glutamine is a critical metabolic bottleneck that can be pharmaco-
logically exploited to prevent the expansion of activated T-cells, and modulate the
immune response during neuroinflammatory diseases such as NSV-induced acute en-
cephalomyelitis.
3.1.2 Glutaminase - GLS1
The enzyme glutaminase converts glutamine to glutamate and is widely expressed and
highly regulated in the immune system [185]. T-cells express kidney-type glutaminase
or GLS1, a distinct isoform expressed in non-hepatic tissues such as the brain, kidneys,
immune system, and transformed cells [118]. Glutaminase mRNA and protein are up
regulated early during T-cell activation when substantial amounts of glutamine are
imported into T-cells [23, 75, 104, 137, 145, 185]. Human T-cells treated in vitro with
either siRNA against GLS1 transcripts or treated with the competitive irreversible
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The concept of metabolic checkpoints
The effective adaptive immune response requires T cells to function in 
various microenvironments, including hostile metabolic conditions. 
Meanwhile, immunological signals actively instruct the intracellular 
metabolic programs and adjust the metabolic state of T cells to adapt 
to changes in extracellular oxygen and nutrient supply or disruption 
of the intracellular metabolic machinery. By analogy to the concept 
of cell-cycle and DNA-damage checkpoints17,18, we consider such 
adaptations as consequences of ‘metabolic checkpoints’. These are 
composed of the following four components: metabolic signals, sen-
sors of those signals, signal transducers and molecular effectors of 
the checkpoint (Fig. 2 and Table 1). The biological consequences of 
engaging such checkpoints in the immune system include not only 
changes in metabolic function but also effects on cell cycle, differen-
tiation, cell death and immunological functions.
Metabolic signals reflect changes in the extracellular nutrient envi-
ronment or intracellular metabolic status. Such signals include metab-
olites involved in cell metabolic pathways or metabolic products, 
byproducts and cofactors such as ATP, NADP+-NADPH, acetyl-CoA 
and reactive oxygen species (ROS). This is fundamentally different 
from the concept of second messengers, such as cAMP-cGMP and 
phosphoinositides, which are not primary signals but instead are 
products of upstream signaling events.
The sensors of a metabolic checkpoint are proteins that physi-
cally interact with and respond to metabolic signals by changes in 
their biological status and consequently initiate downstream signal-
ing events. Of note, the Michaelis constant (Km) of any proposed 
metabolic sensor for its sensed biomolecules must be in the physio-
logical range of the bioavailability of those biomolecules. However, 
direct experimental evidence in support of such a requirement has 
in many cases been largely absent because of the difficulties in quan-
tifying the biomolecules. Unicellular organisms such as bacteria 
and yeast sense and respond to extracellular nutrients through cell- 
surface receptors and transporters19–21. The physical interactions 
among nutrients, receptors and transporters trigger a series of intra-
cellular signaling events that result in adaptive cellular responses. 
Although it is possible that higher organisms use similar mechanisms 
to sense metabolic status and mediate signaling events, direct evi-
dence for this is lacking. Concrete examples of true metabolic sensors 
are discussed below (summary in Table 1).
The subsequent stage of a metabolic-checkpoint response involves 
the engagement of components of signal-transduction pathways 
and their downstream effectors that elicit the appropriate cellular 
responses, including metabolic ‘rewiring’, cell growth, proliferation, 
death and differentiation. Although many examples of translating 
metabolic signaling to cellular response have been described in other 
cellular systems and are reviewed elsewhere22, here we focus on the 
mechanisms that have been demonstrated to be relevant to T cell 
function and adaptive immune responses.
The HIF-1a checkpoint
The cellular and physiological responses to changes in oxygen concen-
trations involve an immediate adaptive response to regulate oxygen 
homeostasis, followed by a signaling response to modulate various 
Figure 1 T cell metabolic reprogramming. 
In naive and memory T cells, mitochondria-
dependent catabolic pathways, including 
glucose oxidation through the tricarboxylic 
acid (TCA) cycle and -oxidation of fatty acids, 
provide most of the metabolic support for 
basic cellular functions. After T cell activation, 
-oxidation rapidly decreases and other 
metabolic pathways (red), including glycolysis 
and glutaminolysis, increase. The glucose 
(Glc) catabolic pathway branches toward the 
production of NADPH and 5-carbon ribose 
(via the pentose phosphate pathway (PPP)) 
at glucose-6-phosphate (G-6-P) and detours 
toward lactate production (aerobic glycolysis) 
at pyruvate. The carbons of glucose are further 
diverted into various synthetic pathways to 
generate the precursors of hexosamines, amino 
acids (such as serine (Ser) and glycine (Gly)) and 
lipids via various metabolic interconnections. 
Meanwhile, mitochondria are fueled by the 
anapleurotic substrate -ketoglutarate ( -KG), 
generated via glutaminolysis. Depending on the 
oxygen supply and the abundance of HIF-1 , 
-ketoglutarate metabolizes in either a clockwise 
or counterclockwise manner through the 
tricarboxylic acid cycle (as presented here) to 
provide energy and a carbon resource for lipids, 
respectively. In addition, glutamine (Gln) serves 
as an important donor of carbon and nitrogen for 
the biosynthesis of hexosamines, nucleotides, 
amino acids and polyamines. Collectively, 
the metabolic reprogramming after T cell 
activation is optimized to support cell growth 
and proliferation by providing carbons and ATP. In functionally differentiated T cells, both CD8+ cytotoxic T cells and CD4+ effector T cells sustain high 
glycolytic activity, whereas CD8+ memory T cells and CD4+ T regulatory cells rely on the -oxidation of fatty acids as a source of energy. F-6-P, fructose-
6-phosphate; 3-P-G, glycerate-3-phosphate; Pyr, pyruvate; Lac, lactate; FFA, free fatty acids; OAA, oxaloacetate; PEP, phosphoenolpyruvate; P-5-C, 1-





































































































non-specific glutaminase inhibitor DON (6-diazo-5-oxo-L-norleucine), fail to initiate
DNA synthesis and proliferate [33]. Moreover, other cells of the immune system,
such as macrophages and neutrophils, show an increase in glutaminase activity upon
activation [35–37, 195]. Additionally, cytokines such as IFN-α, TNF-α, and IL-1β
increase the expression of GLS1 [171,191,195].
3.1.3 T-cell activation
During induction of an immune response to infection, antigen-presenting cells (APC)
in the local lymph node stimulate T-cells by engaging the antigen-specific T-cell
receptor and costimulatory receptors. This process can be recapitulated in vitro by
stimulating T-cells with antibodies to CD3 (T cell receptor) and CD28 (costimulatory
receptor). Cross-linking of CD3 and CD28 stimulates a series of proximal signaling
events that activate the MAPK, NFAT, and NF-B signaling pathways. These tran-
scription factors induce the production of the T cell growth factor interleukin (IL)-2
and expression of the high affinity receptor CD25/IL-2R. IL-2 is released into the
extracellular space and engages the IL-2R on the T-cell plasma membrane in an au-
tocrine and paracrine manner to induce T-cell proliferation. Downstream signaling
from the IL-2R and co-stimulatory receptors activate genes and pathways necessary
for cellular growth and proliferation, the central controller of which is the mTOR
pathway. The mTOR pathway, specifically mTORC1, in T-cells integrates nutrient
and mitogen signals to facilitate translation of essential proteins such as growth fac-
tors [109,117,119]. Currently used immunosuppressive drugs work either by blocking
transcription of the IL-2 gene (i.e. cyclosporin and FK506) or blocking the down-
stream effects of IL-2 on T-cells (i.e. rapamycin).
Expression of early activation markers CD69 and CD25 are dependent on the
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initial activation cascade of NFAT, MAPK and NF-kB which induces transcription of
the IL-2 gene. Hence, surface expression of CD69 and CD25 markers 6-24 hours after
anti-CD3/anti-CD28 stimulation suggests a functional activation cascade. CD25 is
kept on the surface with a IL-2 autocrine and paracrine feedback loop. Moreover,
upregulation of CD98, an amino acid transporter, and CD71 (transferrin receptor)
occurs during late activation.
3.1.4 How does glutamine antagonism inhibit T-cell proliferation?
In the previous chapter we showed that DON had a direct effect on induction of the
peripheral immune response. DON-treated mice had less lymphocyte proliferation
in the peripheral lymph nodes, decreased CNS lymphocyte infiltration, and delayed
viral clearance compared to untreated mice. In this chapter, we explore the direct
effect of glutamine antagonism on lymphocyte proliferation. We show that glutamine
deprivation and treatment with glutamine antagonists, DON and ACI, directly inhibit
lymphocyte growth, proliferation, and cytokine production.
3.2 Material and Methods
3.2.1 Cell Culture and Drugs
Primary lymphocytes were grown in DMEM supplemented with 10% dialyzed FBS
(Invitrogen), penicillin (pen), streptomycin (strep), 2mM glutamine, and 50µM β-
mercaptoethanol (Sigma). Glutamine-deficient DMEM was used in certain experi-
ments. All cells were grown at 37℃ with 5% CO2. Glutamine antagonists, 6-diazo-5-
oxo-L-norleucine (DON; Sigma) and Acivicin (ACI; Sigma) were solubilized in sterile
PBS to prepare 100mM stock solutions. Working dilutions were made in media for
in vitro experiments or in sterile PBS for in vivo experiments. Stock solutions were
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stored at -80℃ and fresh working solutions were created for each use.
3.2.2 In vitro T-cell analysis
CD3+ lymphocytes were purified from the spleens of adult C57BL/6J mice using a
Pan T-cell Isolation Kit (Miltenyi Biotec). For activation, flat bottom 96-well plates
were coated with anti-CD3 (5 µg/mL, 145-2C11 clone, eBiosciences) and anti-CD28
(2.5 µg/mL, 37.51 clone, eBiosciences) for 2h at 37℃ and washed. Prior to culture,
lymphocytes were stained with CFSE (Invitrogen) in PBS with 0.1% BSA for 5 min
at 37℃, washed, and then added at a density of 105 cells/well. Cells were cultured
in glutamine-free or complete (DMEM, 10% dialyzed FBS, 2mM glutamine, NEAAs,
25mM HEPES) media in the presence or absence of DON or ACI 5-20µM. Cells were
stained for CD3, CD4 (PerCPCy 5.5, RM4-5 clone, BD Biosciences), and CD8 as
described above. Viability was assessed at 12h by flow cytometry (BD FACS Canto
II) using a violet fluorescent exclusion dye (Invitrogen) according to the manufacturers
protocol. T-cell proliferation was assessed at 72h by CFSE dilution.
3.2.3 Enzyme immunoassays
For measurement of IFN-γ and IL-2, supernatant fluids collected from culture me-
dia 24h after activation of CD3+ splenocytes with anti-CD3 and CD28 were assayed
for IFN-γ and IL-2 by ELISA(R&D Systems) according to the manufacturer’s proto-
col. Briefly, 96-well plates were coated overnight at 4℃ with capture antibody. Plates
were washed with PBST (PBS with 0.05% Tween-20), blocked with 1% BSA in PBST
for 1h at RT or overnight at 4℃ and washed. Plates were then incubated with de-
tection antibody for 2 hours, washed and subsequently incubated with Streptavidin-
HRP. Color was developed with TMB (3,3,5,5-tetramethylbenzidine) substrate solu-





3.3.1 DON treated T-cell failed to proliferate in vitro.
To determine the effects of glutamine deprivation on T-cell proliferation in vitro, we
stimulated purified primary splenic T-cells with anti-CD3/anti-CD28 and measured
growth and proliferation. Treatment with glutamine antagonists DON or ACI did
not affect cell viability (Supplemental Figure B.2), but drug-treated cells failed to
proliferate. CFSE dilution profiles showed that, like glutamine-deprived lymphocytes,
DON and ACI-treated lymphocytes failed to grow in size (Figure 3.2) and failed to
undergo even one round of division after stimulation (Figure 3.3A). The profiles of
DON and ACI-treated stimulated lymphocytes were similar to glutamine-deprived
stimulated lymphocytes and to unstimulated lymphocytes (Figure 3.3A, B). Because
production of IL-2 is essential for lymphocyte growth in response to stimulation, IL-2
was measured. Glutamine-deprived and DON and ACI-treated lymphocytes did not
produce IL-2 (Figure 3.3C) or IFN-γ (Figure 3.3D) in response to stimulation. We
found similar results using a glutaminase (GLS1) inhibitor, JHU-212 (Supplementary
Figure B.3 ). Additionally, treatment with downstream metabolite, α-ketoglutarate,
failed to fully rescue proliferation in JHU-212 treated lymphocytes (Appendix Figure
B.5). Mice partially deficient in global GLS1 levels showed no difference in IL-2
production or proliferation (Appendix Figure B.4).
3.3.2 DON-treated T-cells failed to fully activate upon stimulation
To determine the effects of glutamine deprivation on T-cell activation, early activa-
tion markers CD69 and CD25 were examined 24h post stimulation. Treatment with
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glutamine antagonists and glutamine deprivation moderately inhibited CD69 expres-
sion while CD25 expression was more severely compromised (Figure 3.4). Growth
and proliferation markers CD98 and CD71 were also analyzed by flow cytometry 24
hours post stimulation (Figure 3.5). T-cells in glutamine-deprived media as well as
cells treated with glutamine antagonists showed a severe defect in the expression of
CD71 which is controlled by the mTOR1 pathway [196]. Therefore we examined the
phosphorylation of ribosomal protein S6 downstream in the mTOR pathway. We
found that DON and JHU-212 inhibited S6 phosphorylation (Appendix Figure B.6),
similar to effect of glutamine deprivation found by others [185].
3.4 Discussion
Glutamine metabolism is important in neuroinflammatory diseases. Glutamine is
utilized by the CNS as a source of the neurotransmitter glutamate and in peripheral
lymphoid tissue as an essential metabolite for growth and proliferation of lympho-
cytes. In this chapter, in vitro experiments using primary mouse T-cells were used
to confirm the immunosuppressive effects of DON. DON-treated CD3+ lymphocytes
failed to grow and proliferate.
The upregulation and regulation of glutamine metabolism is controlled by the
transcription factor Myc which is increased during late stages of T-cell activation
[142, 185]. There has been a recent resurgence of interest in metabolism of immune
cells, in particular T-cells. Recent studies have shown that different T-cell subsets
have different metabolic programs [109]. Activated T-cells upregulate both glutamine
and glucose metabolism with a preference towards glutamine utilization for rapid ex-
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Figure 3.3: DON treated T-cells fail to proliferate and produce IL-2 and IFN-γ
Spleen CD3+ T-cells were stimulated with anti-CD3/anti-CD28. Stimulated cells
were either supplemented with 2mM glutamine (Gln(+), deprived of glutamine (Gln(-
)), or treated with glutamine antagonists (DON and ACI ) in glutamine-supplemented
media. (A) CFSE proliferation assay of stimulated T-cells after 72 h. (B) Quantita-
tion of CFSE data. ELISA analysis of the T-cell growth factor IL-2 (C) and IFN-γ
(D). (Error bars represent +/- SEM of mean of three biological replicates. Data
are representative of at least two independent experiments. ***P <0.001 (One-way






































































































































































































































































































































































































































































































































































































T-regulatory cells survive on fatty acid metabolism [109]. In proliferating cells, glu-
tamine contributes to replenishment of the TCA intermediate α-ketoglutarate and to
the de novo synthesis of nucleotides required for DNA replication during the S-phase
of the cell cycle [54]. The availability of glutamine is an important metabolic check-
point. Cells deprived of glutamine are arrested before reaching the S-Phase of the cell
cycle [54, 185]. In the previous chapter we showed that T-cells of NSV-infected and
DON-treated mice failed to incorporate the thymidine analogue, BrdU (Figure 2.11),
suggesting an arrest in the transition from G1 to S-phase of the cell cycle. We repli-
cated previous findings by others that showed that activated lymphocytes deprived of
extracellular glutamine fail to proliferate or produce cytokines such as IL-2 [23,109].
In addition, we demonstrated that effects of glutamine deprivation can be replicated
using glutamine antagonists DON and ACI. Importantly, unlike in cancer cells, treat-
ing primary T-cells with downstream anaplerotic metabolites like α-ketoglutarate
cannot rescue depreviation of glutamine availability and metabolism in primary lym-
phocytes [185]. We showed that inhibition of proliferation by treatment with the
glutaminase (GLS1) inhibitor JHU-212 cannot be rescued by supplementation with
α-ketoglutarate (Appendix Figure B.5) [152]. However, others have shown limited
rescue of proliferation is possible through the use of nucleotide precursors [185].
The precise mechanism by which cells are able to sense the availability of glutamine
is an area under intense investigation. Recent studies have shown that upstream
glutamine is transport channels and the mTOR pathway play an important role in
sensing the presence of glutamine in cells [47, 123, 128]. Moreover, glutaminolysis
mediated by GLS1 plays key roles in activating the mTOR pathway [47]. Nutrient
sensing via the mTOR pathway may be pivotal role in the late stage of activation
and proliferation of lymphocytes [47,117,123,128,182]. Glutamine deprivation limits
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the phosphorylation of the ribosomal protein S6, a downstream mTOR target, in
T-cells [185]. We showed that treatment with glutamine antagonists, DON, and
GLS1 inhibitor JHU-212 resulted in a similar defect in phospho-S6 levels (Figure
B.6) suggesting, that DON and JHU-212 affect the mTOR pathway. Others, have also
suggested that the MAPK pathway could also play a role [23] and it should be noted
that there can be significant cross talk between the Erk and mTOR pathways [115].
Antigen-specific T-cells must rapidly expand to control invading pathogens. Un-
like proliferating cancer cells that can have heterogeneous metabolism, proliferating
primary T-cells are severely restricted by the availability of glutamine. This rapid
expansion puts extreme metabolic demands on antigen-specific T-cells. Consistent
with other studies we showed a defect in the ability of lymphocytes to proliferate
and produce cytokines under glutamine deprivation. In addition, we showed that
the effects of glutamine deprivation can be achieved by the use of glutamine antag-
onists. Therapeutically modulating glutamine metabolism in primary T-cells might
be important in controlling inflammatory disease.
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A neuroadapted strain (NSV) of Sindbis virus, the prototypic alphavirus causes fatal
encephalomyelitis and paralysis in weanling mice. Previous studies using this model
have shown an interesting non-canonical role for AMPA receptor (AMPAR) antago-
nists on lymphocyte proliferation that has implications for the treatment of CNS and
non-CNS immune-mediated diseases.
AMPA receptors are glutamate-gated ion channels canonically found on mam-
malian neurons for excitatory neurotransmission. AMPA receptors are composed
of a tetrameric combination of subunits, GluR1-4, in the form of a homo or hetero
dimers. The distribution and composition of AMPA receptors in the CNS is heteroge-
nous. The presence of a post-transcriptionally edited GluR2 subunit confers Ca++
impermeability to the ion channel. GluR2 is post-transcriptionally edited with close
to a 100% efficiency in the brain. Hence, GluR2 containing AMPA receptors are
impermeable to calcium in the brain.
Because of the interest in use of neuroprotective agents, such as AMPAR an-
tagonists for prevention of CNS injury, development of drugs that modify AMPAR
signaling is an active area of research [55, 161, 183]. Both competitive and non-
competitive AMPAR antagonists have been developed. The competitive antago-
nists have shown problems with in vivo toxicity and are not currently being de-
veloped for clinical use. The prototype non-competitive antagonists are 2,3 benzo-
diazepine derivatives. The first to be developed was 1-(4-aminophenyl)-4-methyl-
7,8-methylenedioxy-5H-2,3 benzodiazepine (GYKI-52466) [45]. The later generation
4.1. INTRODUCTION
(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo(4,5-h)(2,3) ben-
zodiazepine (GYKI 53773/LY300164/talampanel) is orally available, protects neurons
from excitotoxic damage in animal models of brain trauma, ischemia, and epilepsy
[156,161].
4.1.2 AMPA Receptor antagonists protect from NSV-induced fatal
disease.
GYKI-52466 and Talampanel belong to a class of 2,3 benzodiazepines being developed
to prevent glutamate excitotoxicity in the central nervous system (CNS) [45]. These
drugs allosterically inhibit non-NMDA glutamate-gated ion channels present on neu-
rons. In particular, 2,3 benzodiazepines are highly selective for AMPA receptors over
NMDA and kainate receptors. Previous in vivo studies in our lab have shown that
mice treated with GYKI-52466, or its more potent analogue, Talampanel are protected
from fatal NSV-induced encephalomyelitis and paralysis [65,125]. NMDA antagonist,
MK-801, does not protect these mice from death and paralysis [125]. Treatment did
not affect virus distribution or maximum virus titers, but did dramatically reduce
glial cell activation and inhibited the induction of an antiviral immune response and
CNS inflammation suggesting that this class of drugs might also have a direct effect
on neuroinflammation in addition to preventing glutamate excitotoxicity [65,125].
4.1.3 Do AMPA receptor antagonists have a direct effect on lym-
phocyte proliferation?
Both ionotrophic AMPA and NMDA glutamate receptors are present on peripheral
lymphocytes [57]. However, little is known about the impact of AMPA receptor
antagonists on lymphocyte function. Using primary T-cells we show that AMPA re-
ceptor antagonists have direct effects on lymphocyte activation. Primary lymphocytes
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treated with GYKI fail to proliferate, produce IL-2, express early activation marker
CD69, and have defects in sustained Erk activation. Demonstration that AMPA re-
ceptor antagonists can have a direct effect on the activation of primary T-lymphocyte
has wide implications for the use of AMPA receptor antagonsits for treatment of
neuroinflammatory diseases.
4.2 Material and Methods
4.2.1 Cell Culture and Drugs
Primary lymphocytes were grown in DMEM supplemented with 10% dialyzed FBS
(Invitrogen), non-essential amino acids (NEAAs w/o glutamine), penicillin (pen),
streptomycin (strep), 2mM glutamine, and 50µM β-mercaptoethanol (Sigma). Glutamine-
deficient DMEM was used in certain experiments. EL4.IL2 cells were cultured in
DMEM supplemented with 10% FBS, pen/strep, and 2mM glutamine. All cells were
grown at 37℃ with 5% CO2.
AMPA receptor antagonist, GYKI-52466 (Sigma) was dissolved in 10% DMSO in
0.1M HCl at a concentration of 26mM. GYKI-53655 was solubilized in sterile DMSO
at a 26mM or 100mM stock concentration. Working dilutions were made in media
for in vitro experiments. Ionomycin (1mg/mL) and PMA (Phorbol 12-myristate 13-
acetate) were dissolved in DMSO. Stock solutions were stored at -20℃ and fresh
working solutions were created for each use.
4.2.2 In vitro T-cell analysis
CD3+ lymphocytes were purified from the spleens of adult C57BL/6J (Jackson Labs)
or CD-1 (Charles River) mice using a Pan T-cell Isolation Kit (Miltenyi Biotec). For
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activation, flat bottom 96-well plates were coated with anti-CD3 (5 µg/mL, 145-
2C11 clone, eBiosciences) and anti-CD28 (2.5 µg/mL, 37.51 clone, eBiosciences) for
2h at 37℃ and washed. Prior to culture, lymphocytes were stained with CFSE
(Invitrogen) in PBS with 0.1% BSA for 5 min at 37℃, washed, and then added at
a density of 1-3x105 cells/well. Cells were cultured in glutamine-free or complete
(DMEM, 10% dialyzed FBS, 2mM glutamine, NEAAs, 25mM HEPES) media in the
presence or absence of GYKI-52466 150µM or GYKI-53655 5µM. Cells were stained
for CD3, CD4, and CD8 (BD Biosciences)) as described above. Viability was assessed
at 12h by flow cytometry (BD FACS Canto II) using a violet fluorescent exclusion
dye (Invitrogen) according to the manufacturers protocol. T-cell proliferation was
assessed at 72h by CFSE dilution.
4.2.3 Enzyme immunoassays
For measurement of IL-2, supernatant fluids collected from culture media 12-24h after
activation of CD3+ splenocytes with anti-CD3 and anti-CD28 were assayed for IL-2
(R&D Systems). According to the manufacturer’s protocol. Briefly, 96-well plates
were coated overnight at 4℃ with capture antibody. Plates were washed with PBST
(PBS with 0.05% Tween-20), blocked with 1% BSA in PBST for 1h at RT or overnight
at 4℃ and washed. Plates were then incubated with detection antibody for 2 hours
then washed and subsequently incubated with Streptavidin-HRP. Color was developed
with TMB (3,3,5,5-tetramethylbenzidine) substrate solution (Sigma). After adding




4.3.1 GYKI-53655 inhibits proliferation of primary T-cells
CD3+ lymphocytes from the spleens of C57BL/6 mice were activated in 96-well plates
coated with anti-CD3/anti-CD28 and treated with GYKI-53655 at half-log dose inter-
vals or vehicle (DMSO). Cells treated with GYKI at concentrations greater than 1µM
failed to grow in size and complexity (Figure 4.1A, top panel) and proliferate (Figure
4.1A, bottom panel, B) in response to stimulation compared to vehicle control. At
the higher doses of GYKI stimulated lymphocytes failed to undergo multiple rounds
of proliferation as indicated by their inability to dilute CFSE. At 3µM and 10µM
primary T-cells failed to undergo even one round of replication. IL-2 is an important
T-cell growth factor, essential for lymphocyte growth in response to stimulation. IL-
2 was measured 24 hours post stimulation. GYKI-treated T-cells failed to produce
IL-2 as measured by ELISA. GYKI-52466, the prototypic 2,3 benzodiazepine had the
same effect on lymphocyte proliferation and IL-2 production at higher concentrations
(Figure C.1, 4.2) Supplementing the media with IL-2 failed to rescue lymphocyte
proliferation (Figure 4.2C).
4.3.2 GYKI-53655 inhibits T-cell activation.
To determine if GYKI inhibited T-cell activation. We looked at the early activation
markers CD69 and CD25 in drug-treated and untreated T-cells by flow cytometry.
While CD25 expression was only marginally affected, only half of GYKI treated cells
expressed CD69 (Figure 4.3). GYKI did not affect cell viability compared to vehicle-
treated controls (Figure 4.3A). Previous studies have shown that CD69 is regulated
via the Ras-Erk pathway which is inducible by PMA (Phorbol Myristate Acetate), a
diacylglycerol DAG agonist [38,165]. Treating lymphocytes with PMA alone induced
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CD69 surface expression (Figure 4.4). PMA-induced CD69 expression was inhibited
by drug treatment (Figure 4.4).
4.3.3 GYKI-53655 inhibits sustained Erk activation in EL4.IL2 cells
EL4.IL2 cells are a mouse lymphoblast cell line capable of producing IL-2 after stim-
ulation with PMA or plate bound anti-CD3/anti-CD28 [59,72,154]. IL-2 production
after PMA (Appendix Figure 4.5) or anti-CD3/anti-CD28 (Figure 4.6A) stimulation
was inhibited in drug-treated cells compared to vehicle controls. To determine the
effect of drug treatment on activation of downstream kinases of the Ras pathway, we
probed the phosphorylation status of Jnk, p38, and Erk by western blot. There were
no differences in phosphorylation of Jnk or p38 between drug and vehicle-treated cells.
However, GYKI-treated EL4.IL2 cells showed a defect in sustained Erk phosphoryla-
tion compared to vehicle-treated cells (Figure 4.6B).
4.4 Discussion
Glutamate is the primary excitatory neurotransmitter in the CNS. Mice treated with
AMPA, but not NMDA, receptor antagonists are protected from NSV-induced acute
fatal encephalomyelitis [65, 125]. In these studies, AMPA receptor antagonists pro-
tected mice by inhibiting the induction of the peripheral anti-viral immune response
resulting in delayed viral clearance. In this chapter we examined the direct affect of
AMPA receptor antagonists on CD3+ lymphocyte proliferation.
Primary mouse lymphocytes treated with GYKI-52466 (Figure C.1, 4.2) or GYKI-
53655 failed to produce the essential lymphocyte growth factor IL-2 after stimulation
70
4.4. DISCUSSION









No Stim. 10μM 3μM 1μM 0.3μM 0.1μM Vehicle
Na
























































Figure 4.1: GYKI-53655, inhibits T-cell proliferation in vitro
CD3+ T-cells isolated from mouse spleens were stimulated with anti-CD3/anti-CD28
for 72h. Growth in size (FSC) and complexity (SSC) was measured by flow cytometry
(top panel, (A). Proliferation measured by CFSE dilution assay (bottom panel, (A))
and quantified (B). IL-2 levels of primary CD3+ lymphocytes treated with either
GYKI-53655 (5μM) or Vehicle 24 hours after activation (C). Error bars represent
+/- SEM of mean of three biological replicates. **P <0.01; ***P <0.001 (One-way







































































































Vehicle / IL-2 / GYKI / GYKI+IL-2
Figure 4.2: GYKI-52466 inhibits IL-2 production in primary lymphocytes
Splenocytes or purified CD3+ cells from CD-1 mice were activated using plate bound
anti-CD3/anti-CD28. GYKI-52466 was serially diluted from 300µM - 0µM (Vehi-
cle) and IL-2 production measured by ELISA (A). Proliferation was measured by
CFSE dilution assay via flow cytometry (B). IL-2 failed to rescue proliferation (C)










































































































































Figure 4.3: GYKI-53655 Treatment inhibits T-cell activation.
Purified CD3+ T-cells were stimulated with anti-CD3/anti-CD28. 12h post stimula-
tion, T-cells were stained for CD69(PE)/CD25(APC) and analyzed by flow cytometry.
Percent of double positive (B), CD25+ (C), CD69+ (D) were calculated. Error bars
represent +/- SEM of mean of three biological replicates. Data are representative of
at least two independent experiments. ***P <0.001 (Student’s t-test)
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Figure 4.4: GYKI-52466 inhibits PMA induced CD69 expression.
Purified CD3+ CD-1 mice were harvested and stimulated with Ionomycin, PMA,
or Ionomycin/PMA. Simulated cells were then treated with GYKI-52466 (150µM)








































Figure 4.5: EL4.IL2 cells treated with GYKI-52466 have lower IL-2 production
EL4.IL2 cells activated using PMA (20nM). GYKI-52466 was serially diluted from
200µM - 0µM. Cells were grown in regular media (DMEM, 10% Regular FBS,
Pen/Strep, Glutamine). Cell culture supernatant was collected 12h post activation



























































Figure 4.6: GYKI-53655 inhibits sustained Erk activation in EL4.IL2 cell line.
EL4.IL2 cells were stimulated with anti-CD3/anti-CD28. After 12h post stimulation,
culture supernatant were analyzed for IL-2 via ELISA (A). GYKI-53655 treated and
vehicle treated cells were probed for phospho-p38, phospho-Jnk, phospho-Erk, and
actin over a 12 hour time course (A).
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with anti-CD3/CD28 antibodies ((Figure 4.1). Purified T-cells treated with GYKI-
52466 failed to grow in size or proliferate in vitro. Using a more potent 2, 3 benzo-
diazepine, GYKI-53655, these effects were evident at low micromolar concentrations
(Figure 4.1). The inhibition of CD69 expression (Figure 4.3A, Figure 4.4) suggested
that GYKI had an effect on the Ras-Erk pathway [38,165]. Using the EL4.IL2 mouse
cell line, we showed that GYKI-53655 inhibited sustained Erk pathway activation and
IL-2 production (Figure 4.6).
Interestingly, AMPA receptors are known to be present in various continuously
proliferating cell lines [149]. Treating these transformed cells with glutamate receptor
antagonists in particular GYKI-52466 inhibited their proliferation [149]. We showed
a defect in sustained Erk activation in the EL4.IL2 T-cell line (Figure 4.6) with
GYKI treatment. Studies have shown that AMPA receptors activate the MAPK
pathway, result in sustained Erk activation [172, 184]. Erk signaling is required for
the activation of transcription factor AP-1 involved in IL-2 gene transcription and
sustained activation of Erk is necessary for the upregulation of cell cycle cyclins [61,
154,190]. In one study using a lung cancer cell line, GYKI-52466 treatment inhibited
proliferation by inhibiting Erk phosphorylation while treating with an AMPA agonist
induced Erk phosphorylation [172,184].
T-cells express receptors for a variety of neurotransmitters including glutamate
receptors [8, 57, 71, 106, 150]. Multiple studies have shown that glutamate receptors
of both the ionotrophic and metabotrophic classes can be found in multiple non-
CNS tissues such as heart, kidneys, spleen, and pancreas [10, 46, 71, 85]. Peripheral
glutamate receptors respond to glutamate and this response is inhibited by their re-
spective antagonists. Others have also found a subset of ionotrophic and metatrophic
glutamate receptors including AMPA and NMDA receptor subunits on immune cells
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including T-cells, B-cells, thymocytes, and dendritic cells [1, 57, 106, 189]. These re-
ceptors control a range of functions including calcium signaling, migration, adhesion,
and proliferation. However, these studies have not investigated the effects of allosteric
AMPA receptor antagonists on the proliferation of primary T-cells.
Our studies indicate that AMPA receptor antagonists play a novel role in inhibit-
ing T-cell activation and proliferation. Because the IL-2 induction pathway is highly
conserved between mice and humans and is a major target of current commercial
immunosuppressants such as cyclosporine, this offers an opportunity to investigate
potential novel pathway for immunosupression. These studies showed potent immuno-
logical effects of a glutamate receptor antagonist that have therapeutic implications
for CNS diseases mediated by the immune system and also non-CNS immunological
diseases. AMPA receptor antagonists might provide a novel mechanism of immuno-
suppression with potential benefit in neuroinflammatory disease such as alphaviral
induced viral encephalomyelitis where glutamate excitotoxicty and neuroinflamma-
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5.1 Final Discussion
Inflammation in the nervous system is a necessary part of the response to CNS in-
fection, but also causes neuronal damage in both infectious and autoimmune diseases
of the CNS. We have studied the role of host immune factors in the outcome of viral
encephalomyelitis caused by neuronal infection with the mosquito-borne alphavirus,
neuroadapted Sindbis virus (NSV) [89,90,147]. Previous studies showed that survival
after NSV infection is improved in T-cell deficient mice and in mice with pharmacolog-
ical inhibition of the inflammatory response indicating that development of treatments
that reduce CNS inflammation is an important therapeutic goal [65, 90, 125, 147]. In
addition, glutamate excitoxicity is a major mechanism of damage to mature neurons
in viral encephalitis. Perturbations in glutamate homeostasis as a result of viral repli-
cation [124], neurotoxic cytokines production [21, 141], ineffective clearance [21, 141],
production of excess glutamate [26, 77, 191, 195], and changes in glutamate receptor
composition [193] can cause excitotoxicity.
Therefore, drugs that protect neurons from glutamate excitotoxicity as well as
inhibit the peripheral immune response may provide an option for treatment of viral
encephalitis.
5.1.1 The immune response and glutamate clearance
Despite being present in neurons at millimolar concentrations intracellularly, levels of
glutamate in the extracellular synaptic cleft between neurons are kept low and tightly
regulated to control signaling [112]. Astrocytes utilize glutamate transporters, pre-
dominately GLT-1 (also known as EAAT2) to remove excess glutamate and keep con-
centrations at nanomolar levels in the synaptic cleft [162]. Glutamate is then recycled
back to glutamine by glutamine synthetase and released into the extracellular space
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for uptake by neurons (Figure 1.3B) [20, 130, 131]. The failure of glutamate trans-
porters to clear glutamate and keep glutamate concentrations low in the interstitial
space between neurons can lead to neurodegeneration [146]. Acute inflammation, as
occurs in viral encephalitis, can cause perturbations in glutamate clearance mediated
by inflammatory cytokines [170].
NSV infection induces downregulation of GLT-1 on astrocytes indirectly through
the actions of inflammatory cytokines, IL-1β and TNF-α [21, 140]. BALB/c mice
resistant to NSV-induced fatal disease have lower levels of IL-1β and TNF-α and
better glutamate clearance during NSV infection. Mice deficient in IL-1β and TNF-α
were protected against NSV-induced mortality and paralysis. TNF-α deficient mice
did not show the defects in glutamate transport during NSV infection seen in wild
type mice [21] due to preservation of homeostatic levels of the glutamate transporter
GLT-1 [21]. Similarly, NSV-infected, IL-1β-deficient mice showed limited spinal cord
motor neuron degeneration and limited decrease of the GLT-1 transporter in the spinal
cord [141]. We showed that DON-treated mice protected from paralysis and death
had significantly lower levels of IL-1β and TNF-α mRNA in the brain (Figure 2.8).
Once DON treatment was stopped, IL-1β and TNF-α mRNA expression increased
paralleling the increase in paralysis and mortality (Figure 2.8). DON treatment might
contribute to preserving GLT-1 during NSV infection, thus enabling glutamate clear-
ance.
Immunodeficient SCID mice have lower levels of IL-1β and TNF-α during NSV
infection compared to immunocompetent mice [188]. This suggests that the adap-
tive immune response might play a role in aggravating IL-1β and TNF-α levels by
microglia or macrophages during NSV infection. This hypothesis is supported by
comparison of innate cytokine mRNA expression in the brains of DON-treated and
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PBS-treated mice. Peak IL-1β production occurred on day 5 which coincided with
increased infiltration of T-cells into the CNS and peak IFN-γ production. During
DON treatment both T-cell infiltration and IL-1β production were ablated. (Figure
2.8 ) After halting DON treatment, IL-1β mRNA started to increase which was co-
incident with CD3+ lymphocyte infiltration into the brain (Figure 2.7, Figure 2.8 ).
A recent study with EAE (experimental autoimmune encephalomyelitis), a model for
multiple sclerosis, showed that brain-infiltrating CD3+ lymphocytes, in addition to
activated macrophages, were a potent source of IL-1β. Purified antigen-specific T-cells
in EAE produced 10-fold higher IL-1β in culture. of these lymphocytes with brain
slices showed increased excitatory postsynaptic currents which were ablated by IL-1
receptor antibody treatment [111]. In mice, treatment with IL-1 receptor antibody
limited EAE clinical disease and delayed mortality [111]. Similarly, in NSV infection
continuous exogenous treatment with IL-1β receptor antibody reduced paralysis and
delayed death [79] suggesting that inhibiting IL-1β alone might not be sufficient to
prevent mortality in NSV-induced disease.
NSV-infected mice treated continuously with the neuroprotective drug, minocy-
cline, inhibited the production IL-1β and TNF-α by microglia and were rescued from
fatal paralysis, but delayed treatment reduced the efficacy of this intervention [79].
However, in addition to reducing microglia activation, minocycline has a variety of
effects including inhibition of T-cell proliferation [87, 92, 110]. NSV-infected mice
treated with minocycline had less microglia cell activation and decreased CD45+ cell
infiltration [79]. NSV clearance from the brain and spinal cord was not affected sug-
gesting that antibody responses might be intact [79]. Limited lymphocyte infiltration




How the IL-1β-producing inflammasome is triggered in neurons and microglia
by neurotrophic viruses is still an area of intense study [24]. Though inhibiting IL-
1β production might be beneficial in NSV infection, studies of the mouse model of
West Nile virus (WNV) infection show that inhibiting IL-1β production exacerbates
pathology resulting in reduced survival, increased viral burden, and an exacerbated
inflammatory response in the brain [96]. However, disruption of glutamate clearance
mechanisms has also been implicated in WNV flaccid paralysis [7] and neurotrophic
human coronavirus infection in mice (HCoV) [13]. Similar to NSV, glial activation, IL-
1β and TNF-α production have been associated with neuronal cell death in Japanese
encephalitis virus (JEV) infection [27, 28, 41, 160]. In the model for lethal herpes
simplex virus type 1 (HSV-1) encephalitis both IL-1β and TNFα have a protective
phenotype, limiting viral load, viral dissemination, and facilitating the induction of
the immune response [153]. Patients treated with commercially avaiable anti-TNF-α
antibody, Adalimumab, for rheumatologic disorders show increased risk for HSV-1
and varicella zoster virus-induced encephalitis [11, 14]. Moreover, the inability to
efficiently clear glutamate has been in implicated in a wide range of non-viral diseases
including ALS, Alzheimer’s, Parkinsons, Huntington’s, ischemia, and traumatic brain
injury [192].
These studies suggest that levels of IL-1β and TNF-α play an important role
in modulating glutamate clearance during NSV viral encephalitis. Inhibiting IL-1β




5.1.2 The immune response and glutamate generation
Glutamine metabolism is important in neuroinflammatory diseases. Glutamine is
utilized by the CNS to synthesize the neurotransmitter glutamate and in the im-
mune system as an essential metabolite for growth and proliferation of lymphocytes
in response to antigenic stimulation [109, 126]. In infection with NSV, glutamate
excitotoxicity and the adaptive immune response are implicated in neuronal damage.
Viral infections can increase glutamine metabolism and glutamate production by
microglia, the resident macrophages of the CNS [26, 77]. Evidence from other CNS
virus infections has shown that the conversion of glutamine to glutamate is markedly
increased in neuronal and microglial cells during a variety of neuroinflammatory dis-
eases including viral encephalitis [26, 77]. In microglia, astrocytes, and macrophages
type I interferons, in particular IFN-α, induce transcriptional upregulation of a splice
variant of GLS1 (glutaminase), GAC, by phosphorylation of the STAT1 transcription
factor, transduction, and subsequent binding to the GLS1 promoter. GLS1 promoter
regions of both rodent and human genes have putative STAT1 binding sites. Thus,
IFN-α in the CNS can increase GLS1 synthesis and glutamate production.
Additionally, IL-1β and TNF-α upregulate GLS1 expression in neurons and mi-
croglia resulting in the excess production of glutamate causing autocrine and paracrine
glutamate excitotoxicity [26, 133, 191]. DON treatment of microglia infected with
Japanese encephalitis virus limited TNF-α-induced neurotoxic glutamate production.
In this dissertation, we showed that treatment with DON limited the production of
IL-1β and TNF-α in the brains of NSV-infected mice (Figure 2.8) possibly indirectly
limiting the production of excess glutamate.
Infiltrating immune cells can also exacerbate glutamate excitotoxicity in the CNS
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by providing an additional source of non-neuronal glutamate. In particular, activated
infiltrating CD8+ T-cells are a potent source of non-neuronal glutamate [114]. In-
hibiting glutamine metabolism may also prevent the generation of glutamate from
these non-neuronal cells [26, 77, 195]. Because glutamine metabolism is also involved
in lymphocyte proliferation, glutamine antagonists might prove beneficial in limiting
CNS immune cell infiltration as well as directly curbing the production of glutamate
by lymphocytes already in the CNS.
GLS1 is up regulated during lymphocyte activation and is a major player in glu-
tamine metabolism and signal transduction. Silencing GLS1 via siRNA or pharma-
cologically inhibiting GLS1 [33] through use of GLS1-specific small molecules (e.g.
JHU-212, Appendix Figure B.3) inhibits lymphocyte proliferation. Moreover, small
molecule inhibition of GLS1 in microglia inhibits neurotoxic glutamate production.
Because GLS1 plays a critical role in the nervous systems as well as in the peripheral
immune system, development of GLS1-specific inhibitors might offer a more specific
and targeted way to limit the generation of neurotoxic glutamate production in the
CNS as well as limit peripheral lymphocyte proliferation in neuroinflammatory dis-
ease. However, development of GLS1 specific inhibitors that are effective in vivo have
been plagued by solubility, stability, and specificity issues. BPTES is a very well char-
acterized GLS1 inhibitor but is highly insoluble [42,169]. Developing a soluble, BBB
permeable, and stable GLS1 inhibitor might be a way to prevent immune-induced
neuroinflammatory disease when glutamate excitotoxicity is involved [70].
Improving DON
We observed that continuous treatment with DON even at low doses to be toxic.
Because DON is a competitive glutamine inhibitor, one approach to limit the toxicity
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of DON would be to reduce levels of extracellular glutamine. A recent Phase IIb study
using DON in conjunction with PEGylated glutaminase to deplete serum glutamine
levels showed an increase in effectiveness and tolerability of DON for treatment of late
stage colorectal and lung cancer [86, 122, 180]. Because lymphocytes are sensitive to
extracellular glutamine concentrations [23], depletion of plasma glutamine using this
combinatorial approach might be beneficial in the treatment of neuroinflammatory
and other inflammatory diseases by reducing the dose of DON required to inhibit
lymphocyte proliferation in vivo.
Analogously, we hypothesize that the pharmacological depletion of serum glu-
tamine using high doses of sodium phenylbutyrate, a drug used for treatment of urea
cycle disorders, in conjunction with DON might have a similar effect on increasing
DON efficacy and tolerability [40]. Because glutamine in the CNS is derived from
glucose, serum glutamine depletion should not affect intrinsic CNS glutamate home-
ostasis. Additionally, serum glutamine depletion alone can be beneficial in limiting
the proliferation of lymphocytes, because proliferating lymphocytes are highly sen-
sitive to extracellular glutamine concentrations [23]. This approach can decrease
inflammation by inhibiting induction of the peripheral adaptive immune response.
However, the glutamine serum depletion strategy does not affect generation of
neurotoxic glutamate by microglia. DON has limited blood brain permeability thus,
its actions might be limited to inhibiting the peripheral immune response and might
not directly inhibit the generation of glutamate in the CNS [138]. Modifying DON to
make it more BBB permeable or incorporating DON with blood brain drug carriers
might beneficial in getting DON into the CNS. We showed that a structurally distinct
glutamine antagonist, acivicin (α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid),
was effective in reducing paralysis and morality in NSV-infected mice (Appendix
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Figure 2.2 ). Acivicin has low lipophilicity but can readily pass through BBB by
the use of large amino acid transporters [2,29]. Acivicin might be a good alternative
to DON where direct inhibition of glutamate production by neuronal and microglial
GLS1 is necessary.
5.1.3 Protecting Neurons - Inhibiting response to glutamate
Excess glutamate generation or reduced clearance can lead to glutamate excitotoxic-
ity by promiscuously activating glutamate receptors on neurons that induce signaling
cascades that result in neuronal death by apoptosis or necrosis. Necrotic death re-
sults in further release of intracellular neuronal glutamate and can contribute to by-
stander neuronal death of uninfected nearby neurons during SINV infection [39,124].
Preventing glutamate signaling by allosterically inhibiting AMPA receptors is bene-
ficial in protecting cortical, hippocampal, and especially spinal cord motor neurons
in NSV-induced disease [125]. Motor neurons have calcium permeable AMPA recep-
tors making them sensitive to glutamate excitotoxicity. NSV infected neurons treated
with NASPM, a selective antagonist of calcium permeable AMPA receptors, altered
pathogenesis in rats [39].
GYKI-52466 is the prototypic AMPA receptor antagonist of the 2,3 benzodi-
azepine class that allosterically inhibits AMPA receptors [161]. Inflammatory cy-
tokines such as IL-1β and TNF-α can cause the redistribution of calcium permeable
AMPA receptors during neuroinflammatory disease, increasing sensitivity of cells to
glutamate excitotoxicity [193]. Mice treated with AMPA receptor antagonists, GYKI-
52466 or Talampanel, but not NMDA receptor antagonists survived infection with
limited paralysis [65, 125]. Similar to DON treatment, AMPA receptor antagonists
limited peripheral lymphocyte proliferation, subsequent lymphocyte infiltration into
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the CNS, and as a result delayed viral clearance. This further implicates the adaptive
immune response in morbidity and mortality during NSV infection.
In this dissertation we showed that AMPA receptor antagonists have a direct
effect on the activation of the peripheral immune response. We showed that these
neurotrophic drugs had a direct effect on primary lymphocytes. CD3+ lymphocytes
treated with GYKI-53655, a potent analog of GYKI-52466, showed inhibition of T-
cell activation in vitro. GYKI-53655 inhibited the production of T-cell growth factor,
IL-2, and inhibited the sustained activation of Erk, a critical downstream MAPK
necessary for T-cell activation and proliferation [60].
In infection with neurotrophic human coronavirus (HCoV, causative agent of
SARS) infection in mice, treatment with GYKI-52466 limited microglia but not as-
trocyte activation. Treatment limited neuronal damage, rescued GLT-1 expression
on astrocytes, and rescued mice from paralysis but not mortality. However, unlike
in NSV infection, GYKI-52466 treatment did not have any effect on the viral repli-
cation [12]. In this study, GYKI-52466 was used at 3mg/kg twice daily while in our
previous studies with NSV, GYKI-52466 was used at 10 mg/kg twice daily [125]. In
vitro studies with primary lymphocytes, showed that high doses of GYKI-52466 can
inhibit lymphocyte activation and proliferation (Appendix Figures C.1-4.5. Using the
high affinity derivative, GYKI-53655 (Chapter 4), we replicated primary lymphocyte
inhibition at significantly lower concentrations (Figure 4.1-4.3). Studies show protec-
tive and pathological effects of the immune response in the HCoV model [?, 9, 18].
Immunodeficient mice have delayed mortality, while mice treated with immunsupres-
sive drug, cyclosporine, show increased mortality [18, 83]. It would be interesting to
see if using a higher dose of GYKI-52466 would rescue these mice from death higher
doses protect neurons and inhibit peripheral inflammation in the NSV model [125].
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In total, the studies suggest that AMPA induced glutamate excitotoxicty plays a
role during alphaviral encephalomyelitis and that AMPA receptors antagonists protect
neurons by blocking glutamate excitotoxicty as well as neuroinflammation.
5.1.4 Summary
In this dissertation we showed that DON protects mice from NSV-induced fatal en-
cephalomyelitis by inhibiting the induction of the peripheral immune response and
preventing CNS inflammation. DON and similar glutamine antagonists could have
an ancillary role in preventing glutamate excitotoxicity by inhibiting the generation
of glutamate from neuronal and non-neuronal cells. This might make DON an ideal
candidate drug for treating diseases where glutamate excitotoxicity and inflamma-
tion play a role. In addition we revealed a novel effect of AMPA receptor antagonists
on lymphocyte proliferation by inhibiting T-cell activation through the Erk signaling
pathway resulting in limited IL-2 production.
In total, these studies show that treatment of alphavirus induced encephalomyeli-
tis requires multiple approaches. Glutamate toxicity, immune cell infiltration, and
viral clearance must be addressed to prevent damage and allow clearance of virus
from the CNS. Currently, drugs like DON and AMPA receptor antagonists prevent
neuronal damage but do not help clear virus. Immunomodulatory approaches such
as selectively biasing the qualitative nature of the immune response to mitigate dam-
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A.1.1 Western Blot Analysis
Brain homogenates were prepared in PBS from vehicle and drug-treated NSV-infected
mice as described above. Homogenates were diluted in 2X RIPA (Cell Signaling)
buffer containing protease and phosphatase inhibitors (Sigma), incubated at 4℃ for
15 minutes and then clarified by centrifugation for 30min at maximum speed in a
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microcentrifuge in the cold. Protein concentration was determined using the DC As-
say (BioRad) and samples were boiled in Laemli buffer. Samples were either stored
at -80℃ or were immediately loaded (20-40µg) onto 4-20% gradient gels for elec-
trophoresis. Samples were then transferred onto nitrocellulose membranes (BioRad)
and stained using Ponceau S (Sigma) to determine efficient transfer and loading. The
membrane was blocked for 1h at room temperature in 5% non-fat dry milk (5% milk
in TBS + 0.1% Tween-20), washed for 5min in TBST (TBS with 0.1% Tween-20), and
incubated at 4℃ overnight with rabbit antibody against GFAP (1:1000, Cell Signal-
ing) or caspase-3 (1:1000, Cell Signaling) in TBST with 5% BSA. After washing three
times for 10 minutes in TBST, the membrane was incubated with anti-rabbit IgG
(1:4000, GE Amersham) for one hour at room temperature in TBST with 1% nonfat
dry milk and washed five times with TBST for 10 minutes. The membrane was then
incubated in ECL reagent (GE Amersham) and developed on film (GE Amersham).
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NSV + DON 0.3 mg/kg
NSV 
****
NSV + DON 3 mg/kg 
NSV + DON 1 mg/kg 
Figure A.1: High dose DON is toxic to mice.
C57BL/6 mice were infected with 1000 pfu of NSV intracerebrally and treated every
24h intraperitoneally with glutamine antagonist DON (3 mg/kg, 1 mg/kg, 0.3 mg/kg)
or PBS vehicle (100 - 200µL) i.p. through day 7. For untreated mice (NSV) median
survival was 8 days. Mice treated with DON at 3 mg/kg and 1 mg/kg had a median
survival of 7 and 10 days, respectively. Mice treated with DON at 0.3 mg/kg had
80% survival. ****P <0.0001; Log-rank (Mantel-Cox) survival test.
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NSV + BPTES (5mg/kg)
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Figure A.2: Effect of glutaminase (GLS1) antagonist, BPTES, on NSV in-
fected mice
Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a GLS1 an-
tagonist that allosertically inhibits kidney-type glutaminase isoform, GLS1. C57BL/6
mice (N=5 per group) were infected with 1000 pfu of NSV intracerebrally and treated
every 24h intraperitoneally with BPTES ( 5mg/kg, 1 mg/kg) or Vehicle (20% β-
cyclodextrin in PBS) i.p. through day 7. There were no differences in mortality or
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DON (Sigma) was dissolved in PBS to produce a 100mM stock concentration and
stored in -80℃. Glutaminase (GLS1) inhibitor JHU212 (BSi) and its inactive analog
JHU-365(BSi) were dissolved in DMSO to produce a 100mM stock and stored at
-20℃.
B.1.2 GLS1(+/-) Mice
GLS1(+/-) mice were obtained from the BSi (Brain Science Institute, Johns Hopkins
School of Medicine). CD3+ lymphocytes were isolated and stimulated as previously
described (See 3.2.2). CD3+ T-cells were treated with a suboptimal dose of JHU-212
(2.5µM).
B.1.3 Western Blot Analysis
Homogenates of CD3+ lymphocytes were prepared in RIPA buffer. Homogenates
were diluted in 2X RIPA (Cell Signaling) buffer containing protease and phosphatase
inhibitors (Sigma), incubated at 4℃ for 15 minutes and then clarified by centrifugation
for 30min at maximum speed in a microcentrifuge in the cold. Protein concentration
was determined using the DC Assay (BioRad) and samples were boiled in Laemli
buffer. Samples were either stored at -80℃or loaded (5-15µg) onto 4-20% gradient
gels for electrophoresis. Proteins were then transferred onto nitrocellulose membranes
(BioRad) and stained using Ponceau S (Sigma) to determine efficient transfer and
loading. The membrane was blocked for 1 hour at room temperature in 5% BSA (5%
BSA TBS + 0.1% Tween-20), washed for 5 minutes in TBST (TBS with 0.1% Tween-
20), and incubated at 4℃ overnight with Cell Signaling’s Pathscan Antibody Cocktail
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(1:1000, Cell Signaling) or caspase-3 (1:1000, Cell Signaling) in TBST with 5% BSA.
After washing three times for 10 minutes in TBST, the membrane was incubated with
anti-rabbit IgG (1:4000, GE Amersham) for one hour at room temperature in TBST
with 1% BSA and washed five times with TBST for 10 minutes. The membrane



















































Figure B.1: Glutamine deprivation inhibits lymphocyte proliferation.
CD3+ lymphocytes were isolated from the spleens of C57BL/6 mice and activated
using platebound anti-CD3/anti-CD28 (Stim.) and different media formulations. Pro-
liferation was assessed by CFSE dilution 72h post activation. Error bars represent
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Figure B.2: Effect of different doses of DON on lymphocyte viability, IL-2
production, and proliferation.
CD3+ lymphocytes were isolated from the spleens of C57BL/6 mice and treated with
glutamine antagonist, DON at half-log dose intervals. CD3+ cells were activated
using platebound anti-CD3/anti-CD28 (Stim.). Viability was assessed 12-hours post
activation (A). Supernatant fluids were collected 12-24h post activation and analyzed
for IL-2 production by ELISA (B). Proliferation was assessed by CFSE dilution 72h
post activation relative to vehicle or mock controls (C). Error bars represent +/-
SEM of three replicates per group. **P<0.01; ***P<0.001, (One-Way ANOVA).
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Figure B.3: Effect of different doses of JHU-212 and JHU-365 on lymphocyte
viability, IL-2 production, and proliferation
CD3+ lymphocytes were isolated from the spleens of C57BL/6 mice and treated with
glutamine glutaminase (GLS1) inhibitor, JHU212 or its inactive analog JHU-365 at
half-log dose intervals. CD3+ cells were activated using platebound anti-CD3/anti-
CD28 (Stim.). Viability was assessed 12-hours post activation (A,D). Supernatant
fluids were collected 12-24h post activation and analyzed for IL-2 production via
ELISA (B,E). Proliferation was assessed by CFSE dilution 72h post activation rel-
ative to vehicle or mock controls (C,F). Error bars represent +/- SEM of three





























































Figure B.4: Effect of hetrogenous GLS1 gene expression on lymphocytes pro-
liferation and IL-2 production.
GLS(-/+) have reduced GLS1 activity [113]. CD3+ lymphocytes were isolated from
the spleens of GLS1(+/+) and GLS1(-/+) mice and stimulated (Stim.) with anti-
CD3/anti-CD28. Proliferation was assessed by CFSE dilution 72h post activation(A-
B) and supernatant fluids for IL-2 ELISA were collected 24h post activation (C).
Cells from both GLS1(+/+) and GLS(-/+) mice were treated GLS1 inhibitor JHU-
212 (2.5µM) at a dose that providing only 50% inhibition of proliferation. Error bars








































Figure B.5: α-ketoglutarate (αKG) does not fully rescue proliferation in JHU-
212 treated lymphocytes
CD3+ lymphocytes were isolated from the spleens of C57BL/6 mice and treated with
glutaminse (GLS1) inhibitor, JHU-212 (5µM) or JHU-212 and cell permeating α-
ketoglutarate (from BSi). CD3+ cells were activated using platebound anti-CD3/anti-
CD28 (Stim.). Proliferation was assessed by CFSE dilution 72h post activation. Cells
were treated with DMSO for vehicle control. Error bars represent +/- SEM of three
replicates per group. ***P<0.001, (One-Way ANOVA).
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Glutamine - + + +
Drug - Vehicle DON JHU-212
anti-CD3/anti-CD28
 + + + +
p-S6
Rab11
Figure B.6: DON and JHU-212 treatment inhibits S6 phosphorylation after
stimulation of primary T-cells
CD3+ lymphocytes were isolated from the spleens of C57BL/6 mice and treated
with glutaminse (GLS1) inhibitor, JHU-212 or DON. T-cells were activated using
plate bound anti-CD3/anti-CD28. Lysates were probed for S6 phosphorylation using
western blot with Rab11 serving as a loading control.
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C.1 Supplementary Methods
C.1.1 Drugs
GYKI-53655 (Sigma) was solubilized in DMSO or 10% DMSO in 0.1M HCl to obtain a
26mM or 100mM stock. For in vivo experiments, stock solutions were further diluted
in sterile PBS or complete media.
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C.1.2 Calcium Flux Analysis for GYKI-52466
CD3+ lymphocytes were purified from freshly isolated CD-1 female mouse spleens
by column purification according to the manufacturer’s protocol (Miltenyi Biotec).
Lymphocytes were then resuspended in calcium-free buffer (PBS w/ 25mM HEPES,
0.1% glucose, 1mM sodium pyruvate, and 0.5% BSA) and counted using a hemo-
cytometer. Stock concentrations (10x) of calcium-sensing dyes Fluo-4 AM and Fu-
raRed AM (Invitrogen) were prepared in DMSO with 0.2% pluronic acid (Sigma)
and 25mM probenecid (Invitrogen). Cell density was readjusted to 106 cells/mL in
calcium-free buffer and cells were stained with working concentrations of calcium
sensing dyes (Fluo-4 AM - 1µM and Fura Red AM - 2µM with 0.02% pulronic acid,
2.5mM probenecid, final) for 45 minutes at 37℃. Lymphocytes were then washed with
calcium-free buffer to remove excess dyes and resuspended at an optimal working den-
sity. An aliquot of Fluo-4/Fura Red-labeled lymphocytes were either mock-labeled
(DMSO) or labeled with 1µM Calcein Violet AM (Invitrogen), a viability dye, for 30
minutes at 37℃. Cells were then washed with calcium free buffer to remove excess
dye. Mock-labeled lymphocytes were treated with drug vehicle (10% DMSO in 0.1M
HCl) while Calcein-labeled lymphocytes were treated with GYKI-52466 (Sigma) at
150µM. Mock and GYKI-52466-treated lymphocytes were then incubated at 37℃ for
45-60 minutes before being washed and resuspended in calcium-free buffer. Mock and
GYKI-52466 cells were then incubated with biotin-conjugated anti-CD3 (5µg/mL)
and anti-CD28 (1-2.5µg/mL) antibodies (eBiosciences) for 30 minutes at 4℃ and
subsequently washed in calcium-free buffer and placed on ice. Mock (unlabeled) and
GYKI-52466 (labeled) treated lymphocytes were mixed at a 1:1 ratio in a separate
round bottom test tube and the volume raised to 1mL with calcium free buffer.
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The mixed samples were then run on a BD FACS Canto II set to record on FITC,
PerCP-Cy5.5, and Pacific Blue channels. After 60 seconds into acquistion to estab-
lish a baseline, the samples were treated with streptavidin (10µg/mL, Invitrogen)
to crosslink CD3 and CD28 and acquisition resumed for 120 seconds. At 180 sec-
onds after start of initial acquisition, CaCl2 was added to a final concentration of
approximately 1mM and data acquisition was resumed for another 5 minutes before
being terminated. Flow cytometry data were viewed using FlowJo(Tree Star Inc) and

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure C.2: GYKI-52466 inhibits PMA accelerated IL-2 production in primary
lymphocytes
Purified CD3+ cells from the spleens of CD-1 mice were activated using Iono-
mycin/PMA or plate bound anti-CD3/anti-CD28. Cells were activated using Ion-
omycin/PMA, treated with GYKI, and IL-2 production measured by ELISA at 12h
(A). GYKI treated or untreated cells were activated using anti-CD3/anti-CD28 and
were supplemented with ionomycin or PMA and IL-2 production was measured at 12h







































Figure C.3: CD3+ T-cells treated with GYKI-52466 had a delay in external
calcium flux
Purified CD3+ lymphocytes were labeled with ratiometric calcium indicator Fluo-
4/Fura-Red, pretreated with either Vehicle or GYKI-52466 (150μM). Biotin-
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